<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35333944</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-0738</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>96</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Archives of toxicology</Title>
          <ISOAbbreviation>Arch Toxicol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Toxicology and pharmacology of botulinum and tetanus neurotoxins: an update.</ArticleTitle>
        <Pagination>
          <StartPage>1521</StartPage>
          <EndPage>1539</EndPage>
          <MedlinePgn>1521-1539</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00204-022-03271-9</ELocationID>
        <Abstract>
          <AbstractText>Tetanus and botulinum neurotoxins cause the neuroparalytic syndromes of tetanus and botulism, respectively, by delivering inside different types of neurons, metalloproteases specifically cleaving the SNARE proteins that are essential for the release of neurotransmitters. Research on their mechanism of action is intensively carried out in order to devise improved therapies based on antibodies and chemical drugs. Recently, major results have been obtained with human monoclonal antibodies and with single chain antibodies that have allowed one to neutralize the metalloprotease activity of botulinum neurotoxin type A1 inside neurons. In addition, a method has been devised to induce a rapid molecular evolution of the metalloprotease domain of botulinum neurotoxin followed by selection driven to re-target the metalloprotease activity versus novel targets with respect to the SNARE proteins. At the same time, an intense and wide spectrum clinical research on novel therapeutics based on botulinum neurotoxins is carried out, which are also reviewed here.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pirazzini</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences, University of Padova, Via Ugo Bassi 58/B, 35131, Padova, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centro Interdipartimentale di Ricerca di Miologia, CIR-Myo, University of Padova, Via U. Bassi 58/B, 35131, Padova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Montecucco</LastName>
            <ForeName>Cesare</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0001-7361-5688</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences, University of Padova, Via Ugo Bassi 58/B, 35131, Padova, Italy. cesare.montecucco@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Neuroscience, National Research Council, Via Ugo Bassi 58/B, 35131, Padova, Italy. cesare.montecucco@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rossetto</LastName>
            <ForeName>Ornella</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences, University of Padova, Via Ugo Bassi 58/B, 35131, Padova, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centro Interdipartimentale di Ricerca di Miologia, CIR-Myo, University of Padova, Via U. Bassi 58/B, 35131, Padova, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Neuroscience, National Research Council, Via Ugo Bassi 58/B, 35131, Padova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Arch Toxicol</MedlineTA>
        <NlmUniqueID>0417615</NlmUniqueID>
        <ISSNLinking>0340-5761</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050600">SNARE Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.24.69</RegistryNumber>
          <NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019274" MajorTopicYN="Y">Botulinum Toxins, Type A</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003014" MajorTopicYN="Y">Clostridium botulinum</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009498" MajorTopicYN="N">Neurotoxins</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050600" MajorTopicYN="N">SNARE Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013742" MajorTopicYN="Y">Tetanus</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Botulism</Keyword>
        <Keyword MajorTopicYN="N">Cholinergic</Keyword>
        <Keyword MajorTopicYN="N">Neurotoxins</Keyword>
        <Keyword MajorTopicYN="N">Tetanus</Keyword>
        <Keyword MajorTopicYN="N">Therapy</Keyword>
        <Keyword MajorTopicYN="N">Toxicity</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no conflict of interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>25</Day>
          <Hour>17</Hour>
          <Minute>25</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35333944</ArticleId>
        <ArticleId IdType="pmc">PMC9095541</ArticleId>
        <ArticleId IdType="doi">10.1007/s00204-022-03271-9</ArticleId>
        <ArticleId IdType="pii">10.1007/s00204-022-03271-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Adler M, Scovill J, Parker G, Lebeda F, Piotrowski J, Deshpande SS. Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations. Toxicon. 1995;33:527–537. doi: 10.1016/0041-0101(94)00183-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0041-0101(94)00183-9</ArticleId>
            <ArticleId IdType="pubmed">7570638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agarwal R, Schmidt JJ, Stafford RG, Swaminathan S. Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F. Nat Struct Mol Biol. 2009;16:789–794. doi: 10.1038/nsmb.1626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nsmb.1626</ArticleId>
            <ArticleId IdType="pubmed">19543288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aliprandini E, Takata DY, Lepique A, Kalil J, Boscardin SB, Moro AM. An oligoclonal combination of human monoclonal antibodies able to neutralize tetanus toxin in vivo. Toxicon X. 2019;2:100006. doi: 10.1016/j.toxcx.2019.100006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxcx.2019.100006</ArticleId>
            <ArticleId IdType="pmc">PMC7285915</ArticleId>
            <ArticleId IdType="pubmed">32550563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amalia SN, Uchiyama A, Baral H, et al.  Suppression of neuropeptide by botulinum toxin improves imiquimod-induced psoriasis-like dermatitis via the regulation of neuroimmune system. J Dermatol Sci. 2021;101:58–68. doi: 10.1016/j.jdermsci.2020.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jdermsci.2020.11.003</ArticleId>
            <ArticleId IdType="pubmed">33176965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amezcua M, Cruz RS, Ku A, Moran W, Ortega ME, Salzameda NT. Discovery of dipeptides as potent botulinum neurotoxin A light-chain inhibitors. ACS Med Chem Lett. 2021;12:295–301. doi: 10.1021/acsmedchemlett.0c00674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsmedchemlett.0c00674</ArticleId>
            <ArticleId IdType="pmc">PMC7883461</ArticleId>
            <ArticleId IdType="pubmed">33603978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci. 2008;28:3689–3696. doi: 10.1523/JNEUROSCI.0375-08.2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0375-08.2008</ArticleId>
            <ArticleId IdType="pmc">PMC6671090</ArticleId>
            <ArticleId IdType="pubmed">18385327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnon SS, Schechter R, Inglesby TV, et al.  Botulinum toxin as a biological weapon: medical and public health management. J Am Med Ass. 2001;285:1059–1070. doi: 10.1001/jama.285.8.1059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.285.8.1059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aschenbeck KA, Hordinsky MK, Kennedy WR, et al.  Neuromodulatory treatment of recalcitrant plaque psoriasis with onabotulinumtoxin A. J Am Acad Dermatol. 2018;79:1156–1159. doi: 10.1016/j.jaad.2018.07.058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2018.07.058</ArticleId>
            <ArticleId IdType="pubmed">30420008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azarnia Tehran D, Pirazzini M, Leka O, et al.  Hsp90 is involved in the entry of clostridial neurotoxins into the cytosol of nerve terminals. Cell Microbiol. 2017 doi: 10.1111/cmi.12647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cmi.12647</ArticleId>
            <ArticleId IdType="pubmed">27404998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baek M, DiMaio F, Anishchenko I, et al.  Accurate prediction of protein structures and interactions using a three-track neural network. Science. 2021;373:871–876. doi: 10.1126/science.abj8754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abj8754</ArticleId>
            <ArticleId IdType="pmc">PMC7612213</ArticleId>
            <ArticleId IdType="pubmed">34282049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benoit RM, Frey D, Hilbert M, et al.  Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A. Nature. 2014;505:108–111. doi: 10.1038/nature12732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature12732</ArticleId>
            <ArticleId IdType="pubmed">24240280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bentivoglio AR, Del Grande A, Petracca M, Ialongo T, Ricciardi L. Clinical differences between botulinum neurotoxin type A and B. Toxicon. 2015;107:77–84. doi: 10.1016/j.toxicon.2015.08.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2015.08.001</ArticleId>
            <ArticleId IdType="pubmed">26260691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berardelli A, Conte A. The use of botulinum toxin for treatment of the dystonias. Handb Exp Pharmacol. 2021;263:107–126. doi: 10.1007/164_2019_339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/164_2019_339</ArticleId>
            <ArticleId IdType="pubmed">31820178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bercsenyi K, Schmieg N, Bryson JB, et al.  Nidogens are therapeutic targets for the prevention of tetanus. Science. 2014;346:1118–1123. doi: 10.1126/science.1258138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1258138</ArticleId>
            <ArticleId IdType="pubmed">25430769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhattacharjee Y. Biosecurity: panel selects most dangerous select agents. Science. 2011;332:1491–1492. doi: 10.1126/science.332.6037.1491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.332.6037.1491</ArticleId>
            <ArticleId IdType="pubmed">21700845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bigalke H, Rummel A. Medical aspects of toxin weapons. Toxicology. 2005;214:210–220. doi: 10.1016/j.tox.2005.06.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tox.2005.06.015</ArticleId>
            <ArticleId IdType="pubmed">16087285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Binz T. Clostridial neurotoxin light chains: devices for SNARE cleavage mediated blockade of neurotransmission. Curr Top Microbiol Immunol. 2013;364:139–157. doi: 10.1007/978-3-642-33570-9_7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-642-33570-9_7</ArticleId>
            <ArticleId IdType="pubmed">23239352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Binz T, Rummel A. Cell entry strategy of clostridial neurotoxins. J Neurochem. 2009;109:1584–1595. doi: 10.1111/j.1471-4159.2009.06093.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.2009.06093.x</ArticleId>
            <ArticleId IdType="pubmed">19457120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bloom BS, Payongayong L, Mourin A, Goldberg DJ. Impact of intradermal abobotulinumtoxin A on facial erythema of rosacea. Dermatol Surg. 2015;41(Suppl 1):S9–S16. doi: 10.1097/DSS.0000000000000277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/DSS.0000000000000277</ArticleId>
            <ArticleId IdType="pubmed">25548852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blum FC, Chen C, Kroken AR, Barbieri JT. Tetanus toxin and botulinum toxin a utilize unique mechanisms to enter neurons of the central nervous system. Infect, Immun. 2012;80:1662–1669. doi: 10.1128/IAI.00057-12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.00057-12</ArticleId>
            <ArticleId IdType="pmc">PMC3347426</ArticleId>
            <ArticleId IdType="pubmed">22392932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blum TR, Liu H, Packer MS, et al.  Phage-assisted evolution of botulinum neurotoxin proteases with reprogrammed specificity. Scienc. 2021;371:803–810. doi: 10.1126/science.abf5972.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abf5972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bremer PT, Adler M, Phung CH, Singh AK, Janda KD. Newly designed quinolinol inhibitors mitigate the effects of botulinum neurotoxin A in enzymatic, cell-based, and ex vivo assays. J Med Chem. 2017;60:338–348. doi: 10.1021/acs.jmedchem.6b01393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jmedchem.6b01393</ArticleId>
            <ArticleId IdType="pmc">PMC5496736</ArticleId>
            <ArticleId IdType="pubmed">27966961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brier S, Rasetti-Escargueil C, Wijkhuisen A, et al.  Characterization of a highly neutralizing single monoclonal antibody to botulinum neurotoxin type A. FASEB J. 2021;35:e21540. doi: 10.1096/fj.202002492R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.202002492R</ArticleId>
            <ArticleId IdType="pubmed">33817838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brin MF, Durgam S, Lum A, et al.  OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females. Int Clin Psychopharmacol. 2020;35:19–28. doi: 10.1097/YIC.0000000000000290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/YIC.0000000000000290</ArticleId>
            <ArticleId IdType="pmc">PMC6903360</ArticleId>
            <ArticleId IdType="pubmed">31609787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunger AT, Rummel A. Receptor and substrate interactions of clostridial neurotoxins. Toxicon. 2009;54:550–560. doi: 10.1016/j.toxicon.2008.12.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2008.12.027</ArticleId>
            <ArticleId IdType="pmc">PMC2756235</ArticleId>
            <ArticleId IdType="pubmed">19268493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunt J, Carter AT, Stringer SC, Peck MW. Identification of a novel botulinum neurotoxin gene cluster in enterococcus. FEBS Lett. 2018;592:310–317. doi: 10.1002/1873-3468.12969.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1873-3468.12969</ArticleId>
            <ArticleId IdType="pmc">PMC5838542</ArticleId>
            <ArticleId IdType="pubmed">29323697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caglič D, Krutein MC, Bompiani KM, et al.  Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain. J Med Chem. 2014;57:669–676. doi: 10.1021/jm4012164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm4012164</ArticleId>
            <ArticleId IdType="pmc">PMC3983388</ArticleId>
            <ArticleId IdType="pubmed">24387280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caleo M, Restani L. Direct central nervous system effects of botulinum neurotoxin. Toxicon. 2018;147:68–72. doi: 10.1016/j.toxicon.2017.10.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2017.10.027</ArticleId>
            <ArticleId IdType="pubmed">29111119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caleo M, Schiavo G. Central effects of tetanus and botulinum neurotoxins. Toxicon. 2009;54:593–599. doi: 10.1016/j.toxicon.2008.12.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2008.12.026</ArticleId>
            <ArticleId IdType="pubmed">19264088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caleo M, Spinelli M, Colosimo F, et al.  Transynaptic action of botulinum neurotoxin type A at central cholinergic boutons. J Neurosci. 2018;38:10329–10337. doi: 10.1523/jneurosci.0294-18.2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/jneurosci.0294-18.2018</ArticleId>
            <ArticleId IdType="pmc">PMC6596210</ArticleId>
            <ArticleId IdType="pubmed">30315128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type A formulations injected in the mouse leg. Muscle Nerve. 2009;40:374–380. doi: 10.1002/mus.21343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.21343</ArticleId>
            <ArticleId IdType="pubmed">19618426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CDC, Bioterrorism agents/diseases: https://emergency.cdc.gov/agent/agentlist-category.asp</Citation>
        </Reference>
        <Reference>
          <Citation>Cenciarelli O, Riley PW, Baka A. Biosecurity threat posed by botulinum toxin. Toxins. 2019;11:681. doi: 10.3390/toxins11120681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins11120681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S, Barbieri JT. Engineering botulinum neurotoxin to extend therapeutic intervention. Proc Natl Acad Sci USA. 2009;106:9180–9184. doi: 10.1073/pnas.0903111106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0903111106</ArticleId>
            <ArticleId IdType="pmc">PMC2695098</ArticleId>
            <ArticleId IdType="pubmed">19487672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C, Wang S, Wang H, et al.  Potent neutralization of botulinum neurotoxin/B by synergistic action of antibodies recognizing protein and ganglioside receptor binding domain. PLoS One. 2012;7(8):e43845–e43845. doi: 10.1371/journal.pone.0043845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0043845</ArticleId>
            <ArticleId IdType="pmc">PMC3430616</ArticleId>
            <ArticleId IdType="pubmed">22952786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol. 1992;31:677–679. doi: 10.1002/ana.410310619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410310619</ArticleId>
            <ArticleId IdType="pubmed">1514781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi JE, Werbel T, Wang Z, Wu CC, Yaksh TL, Di Nardo A. Botulinum toxin blocks mast cells and prevents rosacea like inflammation. J Dermatol Sci. 2019;93:58–64. doi: 10.1016/j.jdermsci.2018.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jdermsci.2018.12.004</ArticleId>
            <ArticleId IdType="pmc">PMC7680644</ArticleId>
            <ArticleId IdType="pubmed">30658871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choudhury S, Baker MR, Chatterjee S, Kumar H. Botulinum toxin: an update on pharmacology and newer products in development. Toxins. 2021;13:58. doi: 10.3390/toxins13010058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins13010058</ArticleId>
            <ArticleId IdType="pmc">PMC7828686</ArticleId>
            <ArticleId IdType="pubmed">33466571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colasante C, Rossetto O, Morbiato L, Pirazzini M, Molgó J, Montecucco C. Botulinum neurotoxin type A is internalized and translocated from small synaptic vesicles at the neuromuscular junction. Mol Neurobiol. 2013;48:120–127. doi: 10.1007/s12035-013-8423-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-013-8423-9</ArticleId>
            <ArticleId IdType="pubmed">23471747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Contreras E, Masuyer G, Qureshi N, et al.  A neurotoxin that specifically targets Anopheles mosquitoes. Nat Commun. 2019;10:2869. doi: 10.1038/s41467-019-10732-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-10732-w</ArticleId>
            <ArticleId IdType="pmc">PMC6599013</ArticleId>
            <ArticleId IdType="pubmed">31253776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Currà A, Trompetto C, Abbruzzese G, Berardelli A. Central effects of botulinum toxin type A: evidence and supposition. Mov Disord. 2004;19(Suppl 8):S60–S64. doi: 10.1002/mds.20011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.20011</ArticleId>
            <ArticleId IdType="pubmed">15027056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cutrer FM, Sandroni P, Wendelschafer-Crabb G. Botulinum toxin treatment of cephalalgia alopecia increases substance P and calcitonin gene-related peptide- containing cutaneous nerves in scalp. Cephalalgia. 2010;30:1000–1006. doi: 10.1111/j.1468-2982.2009.01987.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-2982.2009.01987.x</ArticleId>
            <ArticleId IdType="pubmed">19732078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Datta Gupta A, Edwards S, Smith J, et al.  Systematic review and meta-analysis of efficacy of botulinum toxin A for neuropathic pain. Toxins (basel) 2022;14:36. doi: 10.3390/toxins14010036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins14010036</ArticleId>
            <ArticleId IdType="pmc">PMC8780616</ArticleId>
            <ArticleId IdType="pubmed">35051013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Debaisieux S, Encheva V, Chakravarty P, Snijders AP, Schiavo G. Analysis of signaling endosome composition and dynamics using SILAC in embryonic stem cell-derived neurons. Mol Cell Proteomics. 2016;15:542–557. doi: 10.1074/mcp.M115.051649.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/mcp.M115.051649</ArticleId>
            <ArticleId IdType="pmc">PMC4739672</ArticleId>
            <ArticleId IdType="pubmed">26685126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deinhardt K, Salinas S, Verastegui C, Watson R, Worth D, Hanrahan S, Bucci C, Schiavo G. Rab5 and Rab7 control endocytic sorting along the axonal retrograde transport pathway. Neuron. 2006;52:293–305. doi: 10.1016/j.neuron.2006.08.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2006.08.018</ArticleId>
            <ArticleId IdType="pubmed">17046692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deppe J, Weisemann J, Mahrhold S, Rummel A. The 25 kDa HC-N domain of clostridial neurotoxins is indispensable for their neurotoxicity. Toxins. 2020;12:743. doi: 10.3390/toxins12120743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins12120743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolimbek BZ, Aoki KR, Steward LE, Jankovic L, Atassi MZ. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007;44:1029–1041. doi: 10.1016/j.molimm.2006.03.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molimm.2006.03.011</ArticleId>
            <ArticleId IdType="pubmed">16647121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong M, Masuyer G, Stenmark P. Botulinum and tetanus neurotoxins. Annu Rev Biochem. 2019;88:811–837. doi: 10.1146/annurev-biochem-013118-111654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-biochem-013118-111654</ArticleId>
            <ArticleId IdType="pmc">PMC7539302</ArticleId>
            <ArticleId IdType="pubmed">30388027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dover JS, Monheit G, Greener M, Pickett A. Botulinum toxin in aesthetic medicine: myths and realities. Dermatol Surg. 2018;44:249–260. doi: 10.1097/DSS.0000000000001277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/DSS.0000000000001277</ArticleId>
            <ArticleId IdType="pmc">PMC5821482</ArticleId>
            <ArticleId IdType="pubmed">29016535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doxey AC, Mansfield MJ, Montecucco C. Discovery of novel bacterial toxins by genomics and computational biology. Toxicon. 2018;147:2–12. doi: 10.1016/j.toxicon.2018.02.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2018.02.002</ArticleId>
            <ArticleId IdType="pubmed">29438679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol. 2003;49:34–38. doi: 10.1159/000067023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000067023</ArticleId>
            <ArticleId IdType="pubmed">12464716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco Different types of botulinum toxins in humans. Mov Disord. 2004;19:S53–S59. doi: 10.1002/mds.20010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.20010</ArticleId>
            <ArticleId IdType="pubmed">15027055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eleopra R, Montecucco C, Devigili G, et al.  Botulinum neurotoxin serotype D is poorly effective in humans: an in vivo electrophysiological study. Clin Neurophysiol. 2013;124:999–1004. doi: 10.1016/j.clinph.2012.11.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinph.2012.11.004</ArticleId>
            <ArticleId IdType="pubmed">23245668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>et Edgar RC, Taylor J, Lin V, et al.  Petabase-scale sequence alignment catalyses viral discovery. Nature. 2022;602:142–147. doi: 10.1038/s41586-021-04332-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-04332-2</ArticleId>
            <ArticleId IdType="pubmed">35082445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fenicia L, Anniballi F. Infant botulism. Ann Ist Super Sanita. 2009;45:134–146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19636165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finzi E, Wasserman E. Treatment of depression with botulinum toxin A: a case series. Dermatol Surg. 2006;32:645–649. doi: 10.1111/j.1524-4725.2006.32136.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1524-4725.2006.32136.x</ArticleId>
            <ArticleId IdType="pubmed">16706759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer A, Montal M. Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J Biol Chem. 2007;282:29604–29611. doi: 10.1074/jbc.M703619200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M703619200</ArticleId>
            <ArticleId IdType="pubmed">17666397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer A, Montal M. Molecular dissection of botulinum neurotoxin reveals interdomain chaperone function. Toxicon. 2013;75:101–107. doi: 10.1016/j.toxicon.2013.01.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2013.01.007</ArticleId>
            <ArticleId IdType="pmc">PMC3797153</ArticleId>
            <ArticleId IdType="pubmed">23396042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fleck-Derderian S, Shankar M, Rao AK, et al.  The epidemiology of foodborne botulism outbreaks: a systematic review. Clin Infect Dis. 2017;66:S73–S81. doi: 10.1093/cid/cix846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/cix846</ArticleId>
            <ArticleId IdType="pubmed">29293934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fogolari F, Tosatto SC, Muraro L, Montecucco C. Electric dipole reorientation in the interaction of botulinum neurotoxins with neuronal membranes. FEBS Lett. 2009;583:2321–2325. doi: 10.1016/j.febslet.2009.06.046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2009.06.046</ArticleId>
            <ArticleId IdType="pubmed">19576894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>França K, Lotti T. Botulinum toxin for the treatment of depression. Dermatol Ther. 2017 doi: 10.1111/dth.12422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dth.12422</ArticleId>
            <ArticleId IdType="pubmed">29272053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frank SP, Thon KP, Bischoff SC, Lorentz A. SNAP-23 and syntaxin-3 are required for chemokine release by mature human mast cells. Mol Immunol. 2011;49:353–358. doi: 10.1016/j.molimm.2011.09.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molimm.2011.09.011</ArticleId>
            <ArticleId IdType="pubmed">21981832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Rodriguez C, Levy R, Arndt J, et al.  Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol. 2007;25:107–116. doi: 10.1038/nbt1269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt1269</ArticleId>
            <ArticleId IdType="pubmed">17173035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Rodriguez C, Yan S, Isin N, et al.  A four-monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotypes C and D. Toxins. 2021;13:641. doi: 10.3390/toxins13090641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins13090641</ArticleId>
            <ArticleId IdType="pmc">PMC8472335</ArticleId>
            <ArticleId IdType="pubmed">34564645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gardner AP, Barbieri JT. Light chain diversity among the botulinum neurotoxins. Toxins. 2018;10:268. doi: 10.3390/toxins10070268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins10070268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garland M, Babin BM, Miyashita SI, et al.  Covalent modifiers of botulinum neurotoxin counteract toxin persistence. ACS Chem Biol. 2019;14:76–87. doi: 10.1021/acschembio.8b00937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acschembio.8b00937</ArticleId>
            <ArticleId IdType="pmc">PMC7204532</ArticleId>
            <ArticleId IdType="pubmed">30571080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gassner HG, Brissett AE, Otley CC, et al.  Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc. 2006;81:1023–1028. doi: 10.4065/81.8.1023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4065/81.8.1023</ArticleId>
            <ArticleId IdType="pubmed">16901024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghotloo S, Golsaz-Shirazi F, Amiri MM, Jeddi-Tehrani M, Shokri F. Epitope mapping of tetanus toxin by monoclonal antibodies: implication for immunotherapy and vaccine design. Neurotox Res. 2020;37:239–249. doi: 10.1007/s12640-019-00096-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12640-019-00096-w</ArticleId>
            <ArticleId IdType="pubmed">31410686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibbs KL, Kalmar B, Sleigh JN, Greensmith L, Schiavo G. In vivo imaging of axonal transport in murine motor and sensory neurons. J Neurosci Methods. 2016;257:26–33. doi: 10.1016/j.jneumeth.2015.09.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneumeth.2015.09.018</ArticleId>
            <ArticleId IdType="pmc">PMC4666412</ArticleId>
            <ArticleId IdType="pubmed">26424507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Go EJ, Ji J, Kim YH, Berta T, Park CK. Transient receptor potential channels and botulinum neurotoxins in chronic pain. Front Mol Neurosci. 2021;14:772719. doi: 10.3389/fnmol.2021.772719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2021.772719</ArticleId>
            <ArticleId IdType="pmc">PMC8586451</ArticleId>
            <ArticleId IdType="pubmed">34776867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grando SA, Zachary CB. The non-neuronal and nonmuscular effects of botulinum toxin: an opportunity for a deadly molecule to treat disease in the skin and beyond. Br J Dermatol. 2018;178:1011–1019. doi: 10.1111/bjd.16080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjd.16080</ArticleId>
            <ArticleId IdType="pubmed">29086923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grumelli C, Verderio C, Pozzi D, Rossetto O, Montecucco C, Matteoli M. Internalization and mechanism of action of clostridial toxins in neurons. Neurotoxicology. 2005;26:761–767. doi: 10.1016/j.neuro.2004.12.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuro.2004.12.012</ArticleId>
            <ArticleId IdType="pubmed">15925409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guida S, Farnetani F, Nisticò SP, et al.  New trends in botulinum toxin use in dermatology. Dermatol Pract Concept. 2018;8:277–282. doi: 10.5826/dpc.0804a05.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5826/dpc.0804a05</ArticleId>
            <ArticleId IdType="pmc">PMC6246063</ArticleId>
            <ArticleId IdType="pubmed">30479855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guidubaldi A, Fasano A, Ialongo T, et al.  Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Mov Disord. 2011;26:313–319. doi: 10.1002/mds.23473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.23473</ArticleId>
            <ArticleId IdType="pubmed">21259343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Habermann E. 125I-labeled neurotoxin from clostridium botulinum a: preparation, binding to synaptosomes and ascent to the spinal cord, naunyn-schmiedeberg's arch. Pharmacology. 1974;281:47–56.</Citation>
        </Reference>
        <Reference>
          <Citation>Hallett M, Albanese A, Dressler D, et al.  Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94–114. doi: 10.1016/j.toxicon.2012.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2012.12.004</ArticleId>
            <ArticleId IdType="pubmed">23380701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harper CB, Martin S, Nguyen TH, et al.  Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism. J Biol Chem. 2011;286:35966–35976. doi: 10.1074/jbc.M111.283879.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M111.283879</ArticleId>
            <ArticleId IdType="pmc">PMC3195592</ArticleId>
            <ArticleId IdType="pubmed">21832053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harper CB, Papadopulos A, Martin S, et al.  Botulinum neurotoxin type-A enters a non-recycling pool of synaptic vesicles. Sci Rep. 2016;6:19654. doi: 10.1038/srep19654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep19654</ArticleId>
            <ArticleId IdType="pmc">PMC4726273</ArticleId>
            <ArticleId IdType="pubmed">26805017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helton SG, Lohoff FW. Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders. Pharmacogenomics. 2015;16:541–553. doi: 10.2217/pgs.15.15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/pgs.15.15</ArticleId>
            <ArticleId IdType="pubmed">25916524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsieh LF, Wu CW, Chou CC, et al.  Effects of botulinum toxin landmark-guided intra-articular injection in subjects with knee osteoarthritis. PM R. 2016;8:1127–1135. doi: 10.1016/j.pmrj.2016.05.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pmrj.2016.05.009</ArticleId>
            <ArticleId IdType="pubmed">27210235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humphreys IR, Pei J, Baek M, et al.  Computed structures of core eukaryotic protein complexes. Science. 2021;374:eabm4805. doi: 10.1126/science.abm4805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abm4805</ArticleId>
            <ArticleId IdType="pmc">PMC7612107</ArticleId>
            <ArticleId IdType="pubmed">34762488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. J Am Med Ass. 2012;307:1736–1745. doi: 10.1001/jama.2012.505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2012.505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jahn R, Scheller RH. SNAREs-engines for membrane fusion. Nat Rev Mol Cell Biol. 2006;7:631–643. doi: 10.1038/nrm2002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2002</ArticleId>
            <ArticleId IdType="pubmed">16912714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jankovic J. Botulinum toxin: state of the art. Movement Disord. 2017;32:1131–1138. doi: 10.1002/mds.27072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.27072</ArticleId>
            <ArticleId IdType="pubmed">28639368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson EA, Montecucco C. Botulism. Handb Clin Neurol. 2008;91:333–368. doi: 10.1016/S0072-9752(07)01511-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0072-9752(07)01511-4</ArticleId>
            <ArticleId IdType="pubmed">18631849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jost WH, Benecke R, Hauschke D, et al.  Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Dev Ther. 2015;9:1913–1926. doi: 10.2147/dddt.s79193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/dddt.s79193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jumper J, Evans R, Pritzel A, et al.  Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–589. doi: 10.1038/s41586-021-03819-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03819-2</ArticleId>
            <ArticleId IdType="pmc">PMC8371605</ArticleId>
            <ArticleId IdType="pubmed">34265844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kabura L, Ilibagiza D, Menten J, Van den Ende J. Intrathecal vs intramuscular administration of human antitetanus immunoglobulin or equine tetanus antitoxin in the treatment of tetanus: a meta-analysis. Trop Med Int Health. 2006;11:1075–1081. doi: 10.1111/j.1365-3156.2006.01659.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-3156.2006.01659.x</ArticleId>
            <ArticleId IdType="pubmed">16827708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khenioui H, Houvenagel E, Catanzariti JF, Guyot MA, Agnani O, Donze C. Usefulness of intra-articular botulinum toxin injections. A systematic review. Joint Bone Spine. 2016;83:149–154. doi: 10.1016/j.jbspin.2015.10.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jbspin.2015.10.001</ArticleId>
            <ArticleId IdType="pubmed">26645160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim YS, Lee HJ, Cho SH, Lee JD, Kim HS. Early postoperative treatment of thyroidectomy scars using botulinum toxin: a split-scar, double-blind randomized controlled trial. Wound Repair Regen. 2014;22:605–612. doi: 10.1111/wrr.12204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/wrr.12204</ArticleId>
            <ArticleId IdType="pubmed">24898579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiris E, Burnett JC, Kane CD, Bavari S. Recent advances in botulinum neurotoxin inhibitor development. Curr Top Med Chem. 2014;14:2044–2061. doi: 10.2174/1568026614666141022093350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1568026614666141022093350</ArticleId>
            <ArticleId IdType="pubmed">25335887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar G, Agarwal R, Swaminathan S. Small molecule non-peptide inhibitors of botulinum neurotoxin serotype E: structure–activity relationship and a pharmacophore model. Bioorg Med Chem. 2016;24:3978–3985. doi: 10.1016/j.bmc.2016.06.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bmc.2016.06.036</ArticleId>
            <ArticleId IdType="pubmed">27353886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lam KH, Guo Z, Krez N, et al.  A viral-fusion-peptide-like molecular switch drives membrane insertion of botulinum neurotoxin A1. Nat Comm. 2018;9:5367. doi: 10.1038/s41467-018-07789-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-07789-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lam KH, Tremblay JM, Vazquez-Cintron E, et al.  Structural insights into rational design of single-domain antibody-based antitoxins against botulinum neurotoxins. Cell Rep. 2020;30:2526–2539.e6. doi: 10.1016/j.celrep.2020.01.107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2020.01.107</ArticleId>
            <ArticleId IdType="pmc">PMC7138525</ArticleId>
            <ArticleId IdType="pubmed">32101733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawrence GW, Foran P, Oliver Dolly J. Insights into a basis for incomplete inhibition by botulinum toxin A of Ca2+-evoked exocytosis from permeabilised chromaffin cells. Toxicology. 2002;181–182:249–253. doi: 10.1016/s0300-483x(02)00453-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0300-483x(02)00453-5</ArticleId>
            <ArticleId IdType="pubmed">12505320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li B, Peet NP, Butler MM, Burnett JC, Moir DT, Bowlin TL. Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication. Molecules. 2010;16:202–220. doi: 10.3390/molecules16010202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/molecules16010202</ArticleId>
            <ArticleId IdType="pmc">PMC6259422</ArticleId>
            <ArticleId IdType="pubmed">21193845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li ZJ, Park SB, Sohn KC, et al.  Regulation of lipid production by acetylcholine signalling in human sebaceous glands. J Dermatol Sci. 2013;72:116–122. doi: 10.1016/j.jdermsci.2013.06.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jdermsci.2013.06.009</ArticleId>
            <ArticleId IdType="pubmed">23849311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Liu T, Luo W. Botulinum neurotoxin therapy for depression: therapeutic mechanisms and future perspective. Front Psychiatry. 2021;12:584416. doi: 10.3389/fpsyt.2021.584416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fpsyt.2021.584416</ArticleId>
            <ArticleId IdType="pmc">PMC8102733</ArticleId>
            <ArticleId IdType="pubmed">33967844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin L, Olson ME, Eubanks LM, Janda KD. Strategies to counteract botulinum neurotoxin A: nature’s deadliest biomolecule. Acc Chem Res. 2019;52:2322–2331. doi: 10.1021/acs.accounts.9b00261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.accounts.9b00261</ArticleId>
            <ArticleId IdType="pmc">PMC7478247</ArticleId>
            <ArticleId IdType="pubmed">31322847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin L, Olson ME, Sugane T, et al.  Catch and anchor approach to combat both toxicity and longevity of botulinum toxin A. J Med Chem. 2020;63:11100–11120. doi: 10.1021/acs.jmedchem.0c01006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jmedchem.0c01006</ArticleId>
            <ArticleId IdType="pmc">PMC7581224</ArticleId>
            <ArticleId IdType="pubmed">32886509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin L, Turner LD, Šilhár P, Pellett S, Johnson EA, Janda KD. Identification of 3-hydroxy-1,2-dimethylpyridine-4(1H)-thione as a metal-binding motif for the inhibition of botulinum neurotoxin A. RSC Med Chem. 2021;12:137–143. doi: 10.1039/D0MD00320D.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/D0MD00320D</ArticleId>
            <ArticleId IdType="pmc">PMC8130615</ArticleId>
            <ArticleId IdType="pubmed">34046606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magid M, Reichenberg JS, Poth PE, et al.  Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75:837–844. doi: 10.4088/JCP.13m08845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4088/JCP.13m08845</ArticleId>
            <ArticleId IdType="pubmed">24910934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magid M, Keeling BH, Reichenberg JS. Neurotoxins: expanding uses of neuromodulators in medicine-major depressive disorder. Plast Reconstr Surg. 2015;136:111S–119S. doi: 10.1097/PRS.0000000000001733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PRS.0000000000001733</ArticleId>
            <ArticleId IdType="pubmed">26441090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maiarù M, Leese C, Certo M, et al.  Selective neuronal silencing using synthetic botulinum molecules alleviates chronic pain in mice. Sci Transl Med. 2018;10:eaar7384. doi: 10.1126/scitranslmed.aar7384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aar7384</ArticleId>
            <ArticleId IdType="pubmed">30021888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mansfield MJ, Adams JB, Doxey AC. Botulinum neurotoxin homologs in non-Clostridium species. FEBS Lett. 2015;589:342–348. doi: 10.1016/j.febslet.2014.12.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2014.12.018</ArticleId>
            <ArticleId IdType="pubmed">25541486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mansfield MJ, Wentz TG, Zhang S, et al.  Bioinformatic discovery of a toxin family in Chryseobacterium piperi with sequence similarity to botulinum neurotoxins. Sci Rep. 2019;9:1634. doi: 10.1038/s41598-018-37647-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-37647-8</ArticleId>
            <ArticleId IdType="pmc">PMC6367388</ArticleId>
            <ArticleId IdType="pubmed">30733520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marinelli S, Vacca V, Ricordy R, et al.  The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes. PLoS One. 2012;7:e47977. doi: 10.1371/journal.pone.0047977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0047977</ArticleId>
            <ArticleId IdType="pmc">PMC3480491</ArticleId>
            <ArticleId IdType="pubmed">23110146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marlow M, Edwards L, McCrickard L, et al.  Mild botulism from illicitly brewed alcohol in a large prison outbreak in mississippi. Front Publ Health. 2021 doi: 10.3389/fpubh.2021.716615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fpubh.2021.716615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martina E, Diotallevi F, Radi G, Campanati A, Offidani A. Therapeutic use of botulinum neurotoxins in dermatology: systematic review. Toxins. 2021;13:120. doi: 10.3390/toxins13020120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins13020120</ArticleId>
            <ArticleId IdType="pmc">PMC7915854</ArticleId>
            <ArticleId IdType="pubmed">33562846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin-Martin B, Nabokina SM, Blasi J, Lazo PA, Molined F. Involvement of SNAP-23 and syntaxin 6 in human neutrophil exocytosis. Blood. 2000;96:2574–2583. doi: 10.1182/blood.V96.7.2574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.V96.7.2574</ArticleId>
            <ArticleId IdType="pubmed">11001914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masaki C, Sharpley AL, Godlewska BR, et al.  Effects of the potential Lithium-mimetic, ebselen, on brain neurochemistry: a magnetic resonance study. Psychopharmacology. 2016;233:2655–2661. doi: 10.1007/s00213-016-4319-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-016-4319-5</ArticleId>
            <ArticleId IdType="pmc">PMC4917572</ArticleId>
            <ArticleId IdType="pubmed">27256357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masaki C, Sharpley AL, Cooper CM, et al.  Effects of the potential lithium-mimetic, ebselen, on impulsivity and emotional processing. Psychopharmacology. 2016;233:1097–1104. doi: 10.1007/s00213-015-4189-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-015-4189-2</ArticleId>
            <ArticleId IdType="pmc">PMC4759215</ArticleId>
            <ArticleId IdType="pubmed">26758281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maslanka SE, Luquez C, Dykes JK, et al.  A novel botulinum toxin, previously reported as serotype H, has a hybrid structure of known serotypes A and F that is neutralized with serotype A antitoxin. J Infect Dis. 2015;213:379–385. doi: 10.1093/infdis/jiv327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jiv327</ArticleId>
            <ArticleId IdType="pmc">PMC4704661</ArticleId>
            <ArticleId IdType="pubmed">26068781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masuyer G, Chaddock JA, Foster KA, Acharya KR. Engineered botulinum neurotoxins as new therapeutics. Annu Rev Pharmacol Toxicol. 2014;54:27–51. doi: 10.1146/annurev-pharmtox-011613-135935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-pharmtox-011613-135935</ArticleId>
            <ArticleId IdType="pubmed">24016211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matak I, Bach-Rojecky L, Filipovic B, Lackovic Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience. 2011;186:201–207. doi: 10.1016/j.neuroscience.2011.04.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2011.04.026</ArticleId>
            <ArticleId IdType="pubmed">21539899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matak I, Riederer P, Lacković Z. Botulinum toxin's axonal transport from periphery to the spinal cord. Neurochem Int. 2012;61:236–239. doi: 10.1016/j.neuint.2012.05.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuint.2012.05.001</ArticleId>
            <ArticleId IdType="pubmed">22580329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matak I, Rossetto O, Lacković Z. Botulinum toxin type A selectivity for certain types of pain is associated with capsaicin-sensitive neurons. Pain. 2014;155:1516–1526. doi: 10.1016/j.pain.2014.04.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pain.2014.04.027</ArticleId>
            <ArticleId IdType="pubmed">24793910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matteoli M, Verderio C, Rossetto,, et al.  Synaptic vesicle endocytosis mediates the entry of tetanus neurotoxin into hippocampal neurons. Proc Natl Acad Sci USA. 1996;93:13310–13315. doi: 10.1073/pnas.93.23.13310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.93.23.13310</ArticleId>
            <ArticleId IdType="pmc">PMC24089</ArticleId>
            <ArticleId IdType="pubmed">8917587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazzocchio R, Caleo M. More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system. Neuroscientist. 2015;21:44–61. doi: 10.1177/1073858414524633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1073858414524633</ArticleId>
            <ArticleId IdType="pubmed">24576870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McNutt PM, Vazquez-Cintron EJ, Tenezaca L, et al.  Neuronal delivery of antibodies has therapeutic effects in animal models of botulism. Science Transl Med. 2021;13:575. doi: 10.1126/scitranslmed.abd7789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.abd7789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Megighian A, Scorzeto M, Zanini D, et al.  Arg206 of SNAP-25 is essential for neuroexocytosis at the Drosophila melanogaster neuromuscular junction. J Cell Sci. 2010;123:3276–3283. doi: 10.1242/jcs.071316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.071316</ArticleId>
            <ArticleId IdType="pubmed">20826463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Megighian A, Pirazzini M, Fabris F, Rossetto O, Montecucco C. TETANUS and TETANUS NEUROTOXIN: from peripheral uptake to central nervous tissue targets. J Neurochem. 2021;158:1244–1253. doi: 10.1111/jnc.15330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.15330</ArticleId>
            <ArticleId IdType="pubmed">33629408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melo DF, Ramos PM, Antelo DAP, et al.  Is there a rationale for the use of botulinum toxin in the treatment of Androgenetic Alopecia? J Cosmet Dermatol. 2021;20:2093–2095. doi: 10.1111/jocd.14177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jocd.14177</ArticleId>
            <ArticleId IdType="pubmed">33894053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minamitani T, Kiyose K, Otsubo R, et al.  Novel neutralizing human monoclonal antibodies against tetanus neurotoxin. Sci Rep. 2021;11:12134. doi: 10.1038/s41598-021-91597-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-021-91597-2</ArticleId>
            <ArticleId IdType="pmc">PMC8190289</ArticleId>
            <ArticleId IdType="pubmed">34108521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyashita SI, Zhang J, Zhang S, Shoemaker CB, Dong M. Delivery of single-domain antibodies into neurons using a chimeric toxin-based platform is therapeutic in mouse models of botulism. Sci Transl Med. 2021;13:575. doi: 10.1126/scitranslmed.aaz4197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aaz4197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molgo J, Lemeignan M, Thesleff S. Aminoglycosides and 3, 4-diaminopyridine on neuromuscular block caused by botulinum type A toxin. Muscle Nerve. 1987;10:464–470. doi: 10.1002/mus.880100514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.880100514</ArticleId>
            <ArticleId IdType="pubmed">3497343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montal M. Redox regulation of botulinum neurotoxin toxicity: therapeutic implications. Trends Mol Med. 2014;20:602–603. doi: 10.1016/j.molmed.2014.09.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmed.2014.09.005</ArticleId>
            <ArticleId IdType="pmc">PMC4253726</ArticleId>
            <ArticleId IdType="pubmed">25242227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montecucco C, Rasotto MB. On Botulinum neurotoxin variability. Mbio. 2015;6:e02131–e2214. doi: 10.1128/mBio.02131-14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mBio.02131-14</ArticleId>
            <ArticleId IdType="pmc">PMC4313909</ArticleId>
            <ArticleId IdType="pubmed">25564463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montecucco C, Zanotti G. Botulinum neurotoxin A1 likes it double sweet. Nat Struct Mol Biol. 2016;23:619–621. doi: 10.1038/nsmb.3253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nsmb.3253</ArticleId>
            <ArticleId IdType="pubmed">27384187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montecucco C, Schiavo G, Pantano S. SNARE complexes and neuroexocytosis: how many, how close? Trends Biochem Sci. 2005;30:367–372. doi: 10.1016/j.tibs.2005.05.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tibs.2005.05.002</ArticleId>
            <ArticleId IdType="pubmed">15935678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morra ME, Elgebaly A, Elmaraezy A, et al.  Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2016;1:63. doi: 10.1186/s10194-016-0651-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s10194-016-0651-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mukherjee J, Tremblay JM, Leysath CE, Ofori K, Baldwin K, Feng X, et al.  A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS One. 2012;7:e29941. doi: 10.1371/journal.pone.0029941.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0029941</ArticleId>
            <ArticleId IdType="pmc">PMC3253120</ArticleId>
            <ArticleId IdType="pubmed">22238680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muraro L, Tosatto S, Motterlini L, Rossetto O, Montecucco C. The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane. Biochem Biophys Res Commun. 2009;380:76–80. doi: 10.1016/j.bbrc.2009.01.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2009.01.037</ArticleId>
            <ArticleId IdType="pubmed">19161982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naik PP. Utilities of botulinum toxins in dermatology and cosmetology. Clin Cosmet Investig Dermatol. 2021;14:1319–1330. doi: 10.2147/CCID.S332247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CCID.S332247</ArticleId>
            <ArticleId IdType="pmc">PMC8464334</ArticleId>
            <ArticleId IdType="pubmed">34584436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogawa A, Yoshimoto T, Kikuchi H, et al.  Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial. Cerebrovasc Dis. 1999;9:112–118. doi: 10.1159/000015908.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000015908</ArticleId>
            <ArticleId IdType="pubmed">9973655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pantano S, Montecucco C. The blockade of the neurotransmitter release apparatus by botulinum neurotoxins. Cell Mol Life Sci. 2014;71:793–811. doi: 10.1007/s00018-013-1380-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-013-1380-7</ArticleId>
            <ArticleId IdType="pubmed">23749048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pappas G, Kiriaze IJ, Falagas ME. Insights into infectious disease in the era of Hippocrates. Int J Infect Dis. 2008;12:347–350. doi: 10.1016/j.ijid.2007.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijid.2007.11.003</ArticleId>
            <ArticleId IdType="pubmed">18178502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel KB, Cai S, Adler M, Singh BK, Parmar VS, Singh BR. Natural compounds and their analogues as potent antidotes against the most poisonous bacterial toxin. Appl Environ Microbiol. 2018;84:e01280–e1318. doi: 10.1128/AEM.01280-18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AEM.01280-18</ArticleId>
            <ArticleId IdType="pmc">PMC6275346</ArticleId>
            <ArticleId IdType="pubmed">30389764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peck MW, Smith TJ, Anniballi F, et al.  Historical perspectives and guidelines for botulinum neurotoxin subtype nomenclature. Toxins. 2017;9:38. doi: 10.3390/toxins9010038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins9010038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirazzini M, Rossetto O. Challenges in searching for therapeutics against botulinum neurotoxins. Expert Opin Drug Discov. 2017;12:497–510. doi: 10.1080/17460441.2017.1303476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/17460441.2017.1303476</ArticleId>
            <ArticleId IdType="pubmed">28271909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirazzini M, Bordin F, Rossetto O, Shone CC, Binz T, Montecucco C. The thioredoxin reductase-thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals. FEBS Lett. 2013;587:150–155. doi: 10.1016/j.febslet.2012.11.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2012.11.007</ArticleId>
            <ArticleId IdType="pubmed">23178719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirazzini M, Henke T, Rossetto O, et al.  Neutralisation of specific surface carboxylates speeds up translocation of botulinum neurotoxin type B enzymatic domain. FEBS Lett. 2013;587:3831–3836. doi: 10.1016/j.febslet.2013.10.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2013.10.010</ArticleId>
            <ArticleId IdType="pubmed">24157364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirazzini M, Azarnia Tehran D, Zanetti G, et al.  Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins. Cell Rep. 2014;8:1870–1878. doi: 10.1016/j.celrep.2014.08.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2014.08.017</ArticleId>
            <ArticleId IdType="pubmed">25220457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirazzini M, Azarnia Tehran D, Zanetti G, et al.  The thioredoxin reductase–Thioredoxin redox system cleaves the interchain disulphide bond of botulinum neurotoxins on the cytosolic surface of synaptic vesicles. Toxicon. 2015;107:32–36. doi: 10.1016/j.toxicon.2015.06.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2015.06.019</ArticleId>
            <ArticleId IdType="pubmed">26130523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirazzini M, Tehran DA, Leka O, Zanetti G, Rossetto O, Montecucco C. On the translocation of botulinum and tetanus neurotoxins across the membrane of acidic intracellular compartments. Biochim Biophys Acta. 2015 doi: 10.1016/j.bbamem.2015.08.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamem.2015.08.014</ArticleId>
            <ArticleId IdType="pubmed">26307528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69:200–235. doi: 10.1124/pr.116.012658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/pr.116.012658</ArticleId>
            <ArticleId IdType="pmc">PMC5394922</ArticleId>
            <ArticleId IdType="pubmed">28356439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirazzini M, Azarnia Tehran D, Zanetti G, Rossetto O, Montecucco C. Hsp90 and thioredoxin-thioredoxin Reductase enable the catalytic activity of Clostridial neurotoxins inside nerve terminals. Toxicon. 2018;147:32–37. doi: 10.1016/j.toxicon.2017.10.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2017.10.028</ArticleId>
            <ArticleId IdType="pubmed">29111118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirazzini M, Grinzato A, Corti D, et al.  Exceptionally potent human monoclonal antibodies are effective for prophylaxis and therapy of tetanus in mice. J Clin Invest. 2021;131:e151676. doi: 10.1172/JCI151676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI151676</ArticleId>
            <ArticleId IdType="pmc">PMC8592554</ArticleId>
            <ArticleId IdType="pubmed">34618682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pons L, Vilain C, Volteau M, Picaut P. Safety and pharmacodynamics of a novel recombinant botulinum toxin E (rBoNT-E): Results of a phase 1 study in healthy male subjects compared with abobotulinumtoxinA (Dysport®) J Neurol Sci. 2019;407:116516. doi: 10.1016/j.jns.2019.116516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2019.116516</ArticleId>
            <ArticleId IdType="pubmed">31655410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prinetti A, Loberto N, Chigorno V, Sonnino S. Glycosphingolipid behaviour in complex membranes. Biochim Biophys Acta. 2009;1788:184–193. doi: 10.1016/j.bbamem.2008.09.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamem.2008.09.001</ArticleId>
            <ArticleId IdType="pubmed">18835549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian H, Shao F, Lenahan C, Shao A, Li Y. Efficacy and safety of botulinum toxin vs. placebo in depression: a systematic review and meta-analysis of randomized controlled trials. Front Psychiatry. 2020;11:603087. doi: 10.3389/fpsyt.2020.603087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fpsyt.2020.603087</ArticleId>
            <ArticleId IdType="pmc">PMC7746677</ArticleId>
            <ArticleId IdType="pubmed">33343429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao AK, Sobel J, Chatham-Stephens K, Luquez C (2021) Clinical guidelines for diagnosis and treatment of botulism. MMWR Recommendations Rep 70:1–30. 10.15585/mmwr.rr7002a1https://www.cdc.gov/mmwr/volumes/70/rr/rr7002a1.htm</Citation>
        </Reference>
        <Reference>
          <Citation>Rasetti-Escargueil C, Popoff MR. Antibodies and vaccines against botulinum toxins: available measures and novel approaches. Toxins. 2019;11:528. doi: 10.3390/toxins11090528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins11090528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Restani L, Giribaldi F, Manich M, et al.  Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog. 2012;8:e1003087. doi: 10.1371/journal.ppat.1003087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1003087</ArticleId>
            <ArticleId IdType="pmc">PMC3531519</ArticleId>
            <ArticleId IdType="pubmed">23300443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rezasoltani Z, Dadarkhah A, Tabatabaee SM, et al.  Therapeutic effects of intra-articular botulinum neurotoxin versus physical therapy in knee osteoarthritis. Anesth Pain Med. 2021;11:e112789. doi: 10.5812/aapm.112789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5812/aapm.112789</ArticleId>
            <ArticleId IdType="pmc">PMC8438713</ArticleId>
            <ArticleId IdType="pubmed">34540630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ri S, Kivi A, Wissel J. The safety and effect of local botulinum toxin A injections for long-term management of chronic pain in post-herpetic neuralgia: literature review and cases report treated with incobotulinumtoxin A. J Pers Med. 2021;11:758. doi: 10.3390/jpm11080758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jpm11080758</ArticleId>
            <ArticleId IdType="pmc">PMC8400134</ArticleId>
            <ArticleId IdType="pubmed">34442402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rose AE, Goldberg DJ. Safety and efficacy of intradermal injection of botulinum toxin for the treatment of oily skin. Dermatol Surg. 2013;39:443–448. doi: 10.1111/dsu.12097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dsu.12097</ArticleId>
            <ArticleId IdType="pubmed">23293895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossetto O, Montecucco C. Tables of toxicity of botulinum and tetanus neurotoxins. Toxins. 2019 doi: 10.3390/toxins11120686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins11120686</ArticleId>
            <ArticleId IdType="pmc">PMC6950492</ArticleId>
            <ArticleId IdType="pubmed">31771110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12:535–549. doi: 10.1038/nrmicro3295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrmicro3295</ArticleId>
            <ArticleId IdType="pubmed">24975322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossetto O, Pirazzini M, Lista F, Montecucco C. The role of the single interchains disulfide bond in tetanus and botulinum neurotoxins and the development of antitetanus and antibotulism drugs. Cell Microbiol. 2019 doi: 10.1111/cmi.13037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cmi.13037</ArticleId>
            <ArticleId IdType="pmc">PMC6899712</ArticleId>
            <ArticleId IdType="pubmed">31050145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossetto O, Pirazzini M, Lista F, Montecucco C. The role of the single interchain disulfide bond in tetanus and botulinum neurotoxins and the development of antitetanus and antibotulism drugs. Cell Microbiol. 2019;21:e13037. doi: 10.1111/cmi.13037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cmi.13037</ArticleId>
            <ArticleId IdType="pmc">PMC6899712</ArticleId>
            <ArticleId IdType="pubmed">31050145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rummel A. The long journey of botulinum neurotoxins into the synapse. Toxicon. 2015;107:9–24. doi: 10.1016/j.toxicon.2015.09.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2015.09.009</ArticleId>
            <ArticleId IdType="pubmed">26363288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 1992;56:80–99. doi: 10.1128/mr.56.1.80-99.1992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mr.56.1.80-99.1992</ArticleId>
            <ArticleId IdType="pmc">PMC372855</ArticleId>
            <ArticleId IdType="pubmed">1579114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiavo G, Benfenati F, Poulain B, et al.  Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature. 1992;359:832–835. doi: 10.1038/359832a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/359832a0</ArticleId>
            <ArticleId IdType="pubmed">1331807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiavo G, Poulain B, Rossetto O, Benfenati F, Tauc L, Montecucco C. Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc. EMBO J. 1992;11:3577–3583. doi: 10.1002/j.1460-2075.1992.tb05441.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/j.1460-2075.1992.tb05441.x</ArticleId>
            <ArticleId IdType="pmc">PMC556816</ArticleId>
            <ArticleId IdType="pubmed">1396558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiavo G, Santucci A, Dasgupta BR, et al.  Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett. 1993;335:99–103. doi: 10.1016/0014-5793(93)80448-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0014-5793(93)80448-4</ArticleId>
            <ArticleId IdType="pubmed">8243676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmieg N, Menendez G, Schiavo G, Terenzio M. Signalling endosomes in axonal transport: travel updates on the molecular highway. Sem Cell Dev Biol. 2014;27:32–43. doi: 10.1016/j.semcdb.2013.10.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcdb.2013.10.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulze J, Neumann I, Magid M, et al.  Botulinum toxin for the management of depression: an updated review of the evidence and meta-analysis. J Psychiatr Res. 2021;135:332–340. doi: 10.1016/j.jpsychires.2021.01.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpsychires.2021.01.016</ArticleId>
            <ArticleId IdType="pubmed">33578275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044–1049. doi: 10.1016/S0161-6420(80)35127-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0161-6420(80)35127-0</ArticleId>
            <ArticleId IdType="pubmed">7243198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12:924–927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4203467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sen E, Kota KP, Panchal RG, Bavari S, Kiris E. Screening of a focused ubiquitin-proteasome pathway inhibitor library identifies small molecules as novel modulators of botulinum neurotoxin type A toxicity. Front Pharmacol. 2021 doi: 10.3389/fphar.2021.763950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2021.763950</ArticleId>
            <ArticleId IdType="pmc">PMC8666879</ArticleId>
            <ArticleId IdType="pubmed">34912220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharpley A, Williams C, Holder AA, et al.  A phase 2a randomized, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania and hypomania. Psychopharmacology. 2020;237:3773–3782. doi: 10.1007/s00213-020-05654-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-020-05654-1</ArticleId>
            <ArticleId IdType="pmc">PMC7683468</ArticleId>
            <ArticleId IdType="pubmed">32909076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shuo L, Ting Y, KeLun W, Rui Z, Rui Z, Hang W. Efficacy and possible mechanisms of botulinum toxin treatment of oily skin. J Cosmet Dermatol. 2019;18:451–457. doi: 10.1111/jocd.12866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jocd.12866</ArticleId>
            <ArticleId IdType="pubmed">30697928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel LS, Johnson-Winegar AD, Sellin LC. Effect of 3,4-diaminopyridine on the survival of mice injected with botulinum neurotoxin type A, B, E, or F. Toxicol Appl Pharmacol. 1986;84:255–263. doi: 10.1016/0041-008x(86)90133-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0041-008x(86)90133-x</ArticleId>
            <ArticleId IdType="pubmed">3715874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sikorra S, Donald S, Elliot M, et al.  Engineering an effective human SNAP-23 cleaving botulinum neurotoxin A variant. Toxins. 2021;12:804. doi: 10.3390/toxins12120804.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins12120804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000;1:31–39. doi: 10.1038/35036052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35036052</ArticleId>
            <ArticleId IdType="pubmed">11413487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson LL. A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism. Infect Immun. 1986;52:858–862. doi: 10.1128/iai.52.3.858-862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/iai.52.3.858-862</ArticleId>
            <ArticleId IdType="pmc">PMC260939</ArticleId>
            <ArticleId IdType="pubmed">3011675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh N, Halliday AC, Thomas JM, et al.  A safe lithium mimetic for bipolar disorder. Nat Commun. 2013;4:1332. doi: 10.1038/ncomms2320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms2320</ArticleId>
            <ArticleId IdType="pmc">PMC3605789</ArticleId>
            <ArticleId IdType="pubmed">23299882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh N, Sharpley AL, Emir UE, et al.  Effect of the putative lithium mimetic Ebselen on brain Myo-Inositol, sleep, and emotional processing in humans. Neuropsychopharmacology. 2016;41:1768–1778. doi: 10.1038/npp.2015.343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/npp.2015.343</ArticleId>
            <ArticleId IdType="pmc">PMC4770517</ArticleId>
            <ArticleId IdType="pubmed">26593266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sleigh JN, Rossor AM, Fellows AD, Tosolini AP, Schiavo G. Axonal transport and neurological disease. Nat Rev Neurol. 2019;15:691–703. doi: 10.1038/s41582-019-0257-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41582-019-0257-2</ArticleId>
            <ArticleId IdType="pubmed">31558780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sleigh JN, Tosolini AP, Schiavo G. In vivo imaging of anterograde and retrograde axonal transport in rodent peripheral nerves. Methods Mol Biol. 2020;2143:271–292. doi: 10.1007/978-1-0716-0585-1_20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-0716-0585-1_20</ArticleId>
            <ArticleId IdType="pmc">PMC7116510</ArticleId>
            <ArticleId IdType="pubmed">32524487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith TJ, Lou J, Geren IN, et al.  Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun. 2005;73:5450–5457. doi: 10.1128/IAI.73.9.5450-5457.2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.73.9.5450-5457.2005</ArticleId>
            <ArticleId IdType="pmc">PMC1231122</ArticleId>
            <ArticleId IdType="pubmed">16113261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snow DM, Riling K, Kimbler A, et al.  Safety and pharmacokinetics of a four monoclonal antibody combination against botulinum C and D neurotoxins. Antimicrob Agents Chemother. 2019;63:e01270–e1319. doi: 10.1128/AAC.01270-19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.01270-19</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sobel J. Botulism. Clin Infect Dis. 2005;41:1167–1173. doi: 10.1086/444507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/444507</ArticleId>
            <ArticleId IdType="pubmed">16163636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sohrabi C, Goutos I. The use of botulinum toxin in keloid scar management: a literature review. Scars Burn Heal. 2020;6:2059513120926628. doi: 10.1177/2059513120926628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2059513120926628</ArticleId>
            <ArticleId IdType="pmc">PMC7323272</ArticleId>
            <ArticleId IdType="pubmed">32637157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Surana S, Tosolini AP, Meyer IFG, et al.  The travel diaries of tetanus and botulinum neurotoxins. Toxicon. 2018;147:58–67. doi: 10.1016/j.toxicon.2017.10.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2017.10.008</ArticleId>
            <ArticleId IdType="pubmed">29031941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talbet JH, Elnahry AG. OnabotulinumtoxinA for the treatment of headache: an updated review. J Integr Neurosci. 2022;21:37. doi: 10.31083/j.jin2101037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.31083/j.jin2101037</ArticleId>
            <ArticleId IdType="pubmed">35164473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao L, Peng L, Berntsson RPA, et al.  Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors. Nat Commun. 2017;8:53. doi: 10.1038/s41467-017-00064-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-00064-y</ArticleId>
            <ArticleId IdType="pmc">PMC5495808</ArticleId>
            <ArticleId IdType="pubmed">28674381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tehran DA, Pirazzini M. Novel botulinum neurotoxins: exploring underneath the iceberg tip. Toxins. 2018 doi: 10.3390/toxins10050190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins10050190</ArticleId>
            <ArticleId IdType="pmc">PMC5983246</ArticleId>
            <ArticleId IdType="pubmed">29748471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thaker H, Zhang J, Miyashita SI, et al.  Knockin mouse models demonstrate differential contributions of synaptotagmin-1 and -2 as receptors for botulinum neurotoxins. PLoS Pathog. 2021;17:e1009994. doi: 10.1371/journal.ppat.1009994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1009994</ArticleId>
            <ArticleId IdType="pmc">PMC8553082</ArticleId>
            <ArticleId IdType="pubmed">34662366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomic MT, Farr-Jones S, Syar ES, et al.  Neutralizing concentrations of anti-botulinum toxin antibodies positively correlate with mouse neutralization assay results in a guinea pig model. Toxins. 2021;13:671. doi: 10.3390/toxins13090671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins13090671</ArticleId>
            <ArticleId IdType="pmc">PMC8471557</ArticleId>
            <ArticleId IdType="pubmed">34564675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai YC, Maditz R, Kuo C-l, et al.  Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci USA. 2010;107:16554–16559. doi: 10.1073/pnas.1008302107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1008302107</ArticleId>
            <ArticleId IdType="pmc">PMC2944746</ArticleId>
            <ArticleId IdType="pubmed">20823219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai YC, Kotiya A, Kiris E, et al.  Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication. Proc Natl Acad Sci USA. 2017;114:E5158. doi: 10.1073/pnas.1621076114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1621076114</ArticleId>
            <ArticleId IdType="pmc">PMC5495235</ArticleId>
            <ArticleId IdType="pubmed">28584101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tunyasuvunakool K, Adler J, Wu Z, et al.  Highly accurate protein structure prediction for the human proteome. Nature. 2021;596:590–596. doi: 10.1038/s41586-021-03828-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03828-1</ArticleId>
            <ArticleId IdType="pmc">PMC8387240</ArticleId>
            <ArticleId IdType="pubmed">34293799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner LD, Nielsen AL, Lin L, et al.  Use of crystallography and molecular modeling for the inhibition of the botulinum neurotoxin A protease. ACS Med Chem Lett. 2021;12:1318–1324. doi: 10.1021/acsmedchemlett.1c00325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsmedchemlett.1c00325</ArticleId>
            <ArticleId IdType="pmc">PMC8365998</ArticleId>
            <ArticleId IdType="pubmed">34413962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner LD, Nielsen AL, Lin L, et al.  Irreversible inhibition of BoNT/A protease: proximity-driven reactivity contingent upon a bifunctional approach. RSC Med Chem. 2021;12:960–969. doi: 10.1039/d1md00089f.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/d1md00089f</ArticleId>
            <ArticleId IdType="pmc">PMC8221255</ArticleId>
            <ArticleId IdType="pubmed">34223161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vazquez-Cintron E, Machamer J, Ondeck C, et al.  Symptomatic treatment of botulism with a clinically approved small molecule. J Clin Inv Insight. 2020;5:e132891. doi: 10.1172/jci.insight.132891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.132891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vieni C, McGillick B, Kumaran D, Eswaramoorthy E, Kandavelu P, et al.  Structure based discovery of pan active botulinum neurotoxin inhibitors. J Infect Dis Ther. 2018;6:351. doi: 10.4172/2332-0877.1000351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4172/2332-0877.1000351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villar RG, Elliott SP, Davenport KM. Botulism: the many faces of botulinum toxin and its potential for bioterrorism. Infect Dis Clin North Am. 2006;20:313–327. doi: 10.1016/j.idc.2006.02.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.idc.2006.02.003</ArticleId>
            <ArticleId IdType="pubmed">16762741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T, Martin S, Papadopulos A, et al.  Control of autophagosome axonal retrograde flux by presynaptic activity unveiled using botulinum neurotoxin type A. J Neurosci. 2015;35:6179–6194. doi: 10.1523/jneurosci.3757-14.2015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/jneurosci.3757-14.2015</ArticleId>
            <ArticleId IdType="pmc">PMC4787026</ArticleId>
            <ArticleId IdType="pubmed">25878289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Yu R, Fang T, et al.  Tetanus neurotoxin neutralizing antibodies screened from a human immune scFv antibody phage display library. Toxins. 2016;8:266. doi: 10.3390/toxins8090266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins8090266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wu C, Yu J, et al.  Structural basis of tetanus toxin neutralization by native human monoclonal antibodies. Cell Rep. 2021;35:109070. doi: 10.1016/j.celrep.2021.109070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2021.109070</ArticleId>
            <ArticleId IdType="pubmed">33951441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ward NL, Kavlick KD, Diaconu D, Dawes SM, Michaels KA, Gilbert E. Botulinum neurotoxin A decreases infiltrating cutaneous lymphocytes and improves acanthosis in the KC-Tie2 mouse model. J Invest Dermatol. 2012;132:1927–1930. doi: 10.1038/jid.2012.60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jid.2012.60</ArticleId>
            <ArticleId IdType="pmc">PMC3375348</ArticleId>
            <ArticleId IdType="pubmed">22418873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weise D, Weise CM, Naumann M. Central effects of botulinum neurotoxin-evidence from human studies. Toxins. 2019;11:21. doi: 10.3390/toxins11010021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins11010021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiegand H, Erdmann G, Wellhoner HH. 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol. 1976;292:161–165. doi: 10.1007/BF00498587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00498587</ArticleId>
            <ArticleId IdType="pubmed">59905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witmanowski H, Błochowiak K. The whole truth about botulinum toxin—a review. Postepy Dermatol Allergol. 2020;37:853–861. doi: 10.5114/ada.2019.82795.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5114/ada.2019.82795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wright GP. The neurotoxins of Clostridium botulinum and Clostridium tetani. Pharmacol Rev. 1955;7:413–465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13289310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaguchi T, Sano K, Takakura K, et al.  Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group Stroke. 1998;29:12–17.</Citation>
        </Reference>
        <Reference>
          <Citation>Yao G, Zhang S, Mahrhold S, et al.  N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A. Nat Struct Mol Biol. 2016;23:656–662. doi: 10.1038/nsmb.3245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nsmb.3245</ArticleId>
            <ArticleId IdType="pmc">PMC5033645</ArticleId>
            <ArticleId IdType="pubmed">27294781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeh FL, Dong M, Yao J, et al.  SV2 mediates entry of tetanus neurotoxin into central neurons. PLoS Pathog. 2010;6:e1001207. doi: 10.1371/journal.ppat.1001207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1001207</ArticleId>
            <ArticleId IdType="pmc">PMC2991259</ArticleId>
            <ArticleId IdType="pubmed">21124874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yiannakopoulou E. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology. 2015;95:65–69. doi: 10.1159/000370245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000370245</ArticleId>
            <ArticleId IdType="pubmed">25613637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanchi M, Favot F, Bizzarini M, et al.  Botulinum toxin type-A for the treatment of inverse psoriasis. J Eur Acad Dermatol Venereol. 2008;22:431–436. doi: 10.1111/j.1468-3083.2007.02457.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-3083.2007.02457.x</ArticleId>
            <ArticleId IdType="pubmed">18363911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanetti G, Azarnia Tehran D, Pirazzini M, et al.  Inhibition of botulinum neurotoxins interchain disulfide bond reduction prevents the peripheral neuroparalysis of botulism. Biochem Pharmacol. 2015;98:522–530. doi: 10.1016/j.bcp.2015.09.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2015.09.023</ArticleId>
            <ArticleId IdType="pubmed">26449594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanetti G, Mattarei A, Lista F, Rossetto O, Montecucco C, Pirazzini M. Novel small molecule inhibitors that prevent the neuroparalysis of tetanus neurotoxin. Pharmaceuticals. 2021;14:1134. doi: 10.3390/ph14111134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ph14111134</ArticleId>
            <ArticleId IdType="pmc">PMC8618345</ArticleId>
            <ArticleId IdType="pubmed">34832916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Varnum SM. The receptor binding domain of botulinum neurotoxin serotype C binds phosphoinositides. Biochimie. 2012;94:920–923. doi: 10.1016/j.biochi.2011.11.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biochi.2011.11.004</ArticleId>
            <ArticleId IdType="pmc">PMC3277684</ArticleId>
            <ArticleId IdType="pubmed">22120109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S, Masuyer G, Zhang J, et al.  Identification and characterization of a novel botulinum neurotoxin. Nat Commun. 2017;8:14130. doi: 10.1038/ncomms14130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms14130</ArticleId>
            <ArticleId IdType="pmc">PMC5543303</ArticleId>
            <ArticleId IdType="pubmed">28770820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S, Lebreton F, Mansfield MJ, et al.  Identification of a botulinum neurotoxin-like toxin in a commensal strain of Enterococcus faecium. Cell Host Microbe. 2018;23:169–176. doi: 10.1016/j.chom.2017.12.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2017.12.018</ArticleId>
            <ArticleId IdType="pmc">PMC5926203</ArticleId>
            <ArticleId IdType="pubmed">29396040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang G, Yu R, Chi X, et al.  Tetanus vaccine-induced human neutralizing antibodies provide full protection against neurotoxin challenge in mice. Int Immunopharmacol. 2021;91:107297. doi: 10.1016/j.intimp.2020.107297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2020.107297</ArticleId>
            <ArticleId IdType="pubmed">33360088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y, Yu S, Zhao J, et al.  Effectiveness and safety of botulinum toxin type A in the treatment of androgenetic alopecia. Biomed Res Int. 2020;2020:1–7. doi: 10.1155/2020/1501893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2020/1501893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ziade M, Domergue S, Batifol D, et al.  Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomised study. J Plast Reconstr Aesthet Surg. 2013;66:209–214. doi: 10.1016/j.bjps.2012.09.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bjps.2012.09.012</ArticleId>
            <ArticleId IdType="pubmed">23102873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zornetta I, Azarnia Tehran D, Arrigoni G, et al.  The first non Clostridial botulinum-like toxin cleaves VAMP within the juxtamembrane domain. Sci Rep. 2016;6:30257. doi: 10.1038/srep30257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep30257</ArticleId>
            <ArticleId IdType="pmc">PMC4957215</ArticleId>
            <ArticleId IdType="pubmed">27443638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuverink M, Bluma M, Barbieri JT, Krantz B. Tetanus toxin cis-loop contributes to light-chain translocation. mSphere. 2020;5:e00244-20. doi: 10.1128/mSphere.00244-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mSphere.00244-20</ArticleId>
            <ArticleId IdType="pmc">PMC7203457</ArticleId>
            <ArticleId IdType="pubmed">32376703</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35333944</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-0738</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>96</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Archives of toxicology</Title>
          <ISOAbbreviation>Arch Toxicol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Toxicology and pharmacology of botulinum and tetanus neurotoxins: an update.</ArticleTitle>
        <Pagination>
          <StartPage>1521</StartPage>
          <EndPage>1539</EndPage>
          <MedlinePgn>1521-1539</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00204-022-03271-9</ELocationID>
        <Abstract>
          <AbstractText>Tetanus and botulinum neurotoxins cause the neuroparalytic syndromes of tetanus and botulism, respectively, by delivering inside different types of neurons, metalloproteases specifically cleaving the SNARE proteins that are essential for the release of neurotransmitters. Research on their mechanism of action is intensively carried out in order to devise improved therapies based on antibodies and chemical drugs. Recently, major results have been obtained with human monoclonal antibodies and with single chain antibodies that have allowed one to neutralize the metalloprotease activity of botulinum neurotoxin type A1 inside neurons. In addition, a method has been devised to induce a rapid molecular evolution of the metalloprotease domain of botulinum neurotoxin followed by selection driven to re-target the metalloprotease activity versus novel targets with respect to the SNARE proteins. At the same time, an intense and wide spectrum clinical research on novel therapeutics based on botulinum neurotoxins is carried out, which are also reviewed here.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pirazzini</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences, University of Padova, Via Ugo Bassi 58/B, 35131, Padova, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centro Interdipartimentale di Ricerca di Miologia, CIR-Myo, University of Padova, Via U. Bassi 58/B, 35131, Padova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Montecucco</LastName>
            <ForeName>Cesare</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0001-7361-5688</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences, University of Padova, Via Ugo Bassi 58/B, 35131, Padova, Italy. cesare.montecucco@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Neuroscience, National Research Council, Via Ugo Bassi 58/B, 35131, Padova, Italy. cesare.montecucco@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rossetto</LastName>
            <ForeName>Ornella</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences, University of Padova, Via Ugo Bassi 58/B, 35131, Padova, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centro Interdipartimentale di Ricerca di Miologia, CIR-Myo, University of Padova, Via U. Bassi 58/B, 35131, Padova, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Neuroscience, National Research Council, Via Ugo Bassi 58/B, 35131, Padova, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Arch Toxicol</MedlineTA>
        <NlmUniqueID>0417615</NlmUniqueID>
        <ISSNLinking>0340-5761</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050600">SNARE Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.24.69</RegistryNumber>
          <NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019274" MajorTopicYN="Y">Botulinum Toxins, Type A</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003014" MajorTopicYN="Y">Clostridium botulinum</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009498" MajorTopicYN="N">Neurotoxins</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050600" MajorTopicYN="N">SNARE Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013742" MajorTopicYN="Y">Tetanus</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Botulism</Keyword>
        <Keyword MajorTopicYN="N">Cholinergic</Keyword>
        <Keyword MajorTopicYN="N">Neurotoxins</Keyword>
        <Keyword MajorTopicYN="N">Tetanus</Keyword>
        <Keyword MajorTopicYN="N">Therapy</Keyword>
        <Keyword MajorTopicYN="N">Toxicity</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no conflict of interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>25</Day>
          <Hour>17</Hour>
          <Minute>25</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35333944</ArticleId>
        <ArticleId IdType="pmc">PMC9095541</ArticleId>
        <ArticleId IdType="doi">10.1007/s00204-022-03271-9</ArticleId>
        <ArticleId IdType="pii">10.1007/s00204-022-03271-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Adler M, Scovill J, Parker G, Lebeda F, Piotrowski J, Deshpande SS. Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations. Toxicon. 1995;33:527–537. doi: 10.1016/0041-0101(94)00183-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0041-0101(94)00183-9</ArticleId>
            <ArticleId IdType="pubmed">7570638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agarwal R, Schmidt JJ, Stafford RG, Swaminathan S. Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F. Nat Struct Mol Biol. 2009;16:789–794. doi: 10.1038/nsmb.1626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nsmb.1626</ArticleId>
            <ArticleId IdType="pubmed">19543288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aliprandini E, Takata DY, Lepique A, Kalil J, Boscardin SB, Moro AM. An oligoclonal combination of human monoclonal antibodies able to neutralize tetanus toxin in vivo. Toxicon X. 2019;2:100006. doi: 10.1016/j.toxcx.2019.100006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxcx.2019.100006</ArticleId>
            <ArticleId IdType="pmc">PMC7285915</ArticleId>
            <ArticleId IdType="pubmed">32550563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amalia SN, Uchiyama A, Baral H, et al.  Suppression of neuropeptide by botulinum toxin improves imiquimod-induced psoriasis-like dermatitis via the regulation of neuroimmune system. J Dermatol Sci. 2021;101:58–68. doi: 10.1016/j.jdermsci.2020.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jdermsci.2020.11.003</ArticleId>
            <ArticleId IdType="pubmed">33176965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amezcua M, Cruz RS, Ku A, Moran W, Ortega ME, Salzameda NT. Discovery of dipeptides as potent botulinum neurotoxin A light-chain inhibitors. ACS Med Chem Lett. 2021;12:295–301. doi: 10.1021/acsmedchemlett.0c00674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsmedchemlett.0c00674</ArticleId>
            <ArticleId IdType="pmc">PMC7883461</ArticleId>
            <ArticleId IdType="pubmed">33603978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci. 2008;28:3689–3696. doi: 10.1523/JNEUROSCI.0375-08.2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0375-08.2008</ArticleId>
            <ArticleId IdType="pmc">PMC6671090</ArticleId>
            <ArticleId IdType="pubmed">18385327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnon SS, Schechter R, Inglesby TV, et al.  Botulinum toxin as a biological weapon: medical and public health management. J Am Med Ass. 2001;285:1059–1070. doi: 10.1001/jama.285.8.1059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.285.8.1059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aschenbeck KA, Hordinsky MK, Kennedy WR, et al.  Neuromodulatory treatment of recalcitrant plaque psoriasis with onabotulinumtoxin A. J Am Acad Dermatol. 2018;79:1156–1159. doi: 10.1016/j.jaad.2018.07.058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2018.07.058</ArticleId>
            <ArticleId IdType="pubmed">30420008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azarnia Tehran D, Pirazzini M, Leka O, et al.  Hsp90 is involved in the entry of clostridial neurotoxins into the cytosol of nerve terminals. Cell Microbiol. 2017 doi: 10.1111/cmi.12647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cmi.12647</ArticleId>
            <ArticleId IdType="pubmed">27404998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baek M, DiMaio F, Anishchenko I, et al.  Accurate prediction of protein structures and interactions using a three-track neural network. Science. 2021;373:871–876. doi: 10.1126/science.abj8754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abj8754</ArticleId>
            <ArticleId IdType="pmc">PMC7612213</ArticleId>
            <ArticleId IdType="pubmed">34282049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benoit RM, Frey D, Hilbert M, et al.  Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A. Nature. 2014;505:108–111. doi: 10.1038/nature12732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature12732</ArticleId>
            <ArticleId IdType="pubmed">24240280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bentivoglio AR, Del Grande A, Petracca M, Ialongo T, Ricciardi L. Clinical differences between botulinum neurotoxin type A and B. Toxicon. 2015;107:77–84. doi: 10.1016/j.toxicon.2015.08.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2015.08.001</ArticleId>
            <ArticleId IdType="pubmed">26260691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berardelli A, Conte A. The use of botulinum toxin for treatment of the dystonias. Handb Exp Pharmacol. 2021;263:107–126. doi: 10.1007/164_2019_339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/164_2019_339</ArticleId>
            <ArticleId IdType="pubmed">31820178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bercsenyi K, Schmieg N, Bryson JB, et al.  Nidogens are therapeutic targets for the prevention of tetanus. Science. 2014;346:1118–1123. doi: 10.1126/science.1258138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1258138</ArticleId>
            <ArticleId IdType="pubmed">25430769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhattacharjee Y. Biosecurity: panel selects most dangerous select agents. Science. 2011;332:1491–1492. doi: 10.1126/science.332.6037.1491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.332.6037.1491</ArticleId>
            <ArticleId IdType="pubmed">21700845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bigalke H, Rummel A. Medical aspects of toxin weapons. Toxicology. 2005;214:210–220. doi: 10.1016/j.tox.2005.06.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tox.2005.06.015</ArticleId>
            <ArticleId IdType="pubmed">16087285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Binz T. Clostridial neurotoxin light chains: devices for SNARE cleavage mediated blockade of neurotransmission. Curr Top Microbiol Immunol. 2013;364:139–157. doi: 10.1007/978-3-642-33570-9_7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-642-33570-9_7</ArticleId>
            <ArticleId IdType="pubmed">23239352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Binz T, Rummel A. Cell entry strategy of clostridial neurotoxins. J Neurochem. 2009;109:1584–1595. doi: 10.1111/j.1471-4159.2009.06093.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.2009.06093.x</ArticleId>
            <ArticleId IdType="pubmed">19457120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bloom BS, Payongayong L, Mourin A, Goldberg DJ. Impact of intradermal abobotulinumtoxin A on facial erythema of rosacea. Dermatol Surg. 2015;41(Suppl 1):S9–S16. doi: 10.1097/DSS.0000000000000277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/DSS.0000000000000277</ArticleId>
            <ArticleId IdType="pubmed">25548852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blum FC, Chen C, Kroken AR, Barbieri JT. Tetanus toxin and botulinum toxin a utilize unique mechanisms to enter neurons of the central nervous system. Infect, Immun. 2012;80:1662–1669. doi: 10.1128/IAI.00057-12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.00057-12</ArticleId>
            <ArticleId IdType="pmc">PMC3347426</ArticleId>
            <ArticleId IdType="pubmed">22392932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blum TR, Liu H, Packer MS, et al.  Phage-assisted evolution of botulinum neurotoxin proteases with reprogrammed specificity. Scienc. 2021;371:803–810. doi: 10.1126/science.abf5972.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abf5972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bremer PT, Adler M, Phung CH, Singh AK, Janda KD. Newly designed quinolinol inhibitors mitigate the effects of botulinum neurotoxin A in enzymatic, cell-based, and ex vivo assays. J Med Chem. 2017;60:338–348. doi: 10.1021/acs.jmedchem.6b01393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jmedchem.6b01393</ArticleId>
            <ArticleId IdType="pmc">PMC5496736</ArticleId>
            <ArticleId IdType="pubmed">27966961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brier S, Rasetti-Escargueil C, Wijkhuisen A, et al.  Characterization of a highly neutralizing single monoclonal antibody to botulinum neurotoxin type A. FASEB J. 2021;35:e21540. doi: 10.1096/fj.202002492R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.202002492R</ArticleId>
            <ArticleId IdType="pubmed">33817838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brin MF, Durgam S, Lum A, et al.  OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females. Int Clin Psychopharmacol. 2020;35:19–28. doi: 10.1097/YIC.0000000000000290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/YIC.0000000000000290</ArticleId>
            <ArticleId IdType="pmc">PMC6903360</ArticleId>
            <ArticleId IdType="pubmed">31609787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunger AT, Rummel A. Receptor and substrate interactions of clostridial neurotoxins. Toxicon. 2009;54:550–560. doi: 10.1016/j.toxicon.2008.12.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2008.12.027</ArticleId>
            <ArticleId IdType="pmc">PMC2756235</ArticleId>
            <ArticleId IdType="pubmed">19268493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunt J, Carter AT, Stringer SC, Peck MW. Identification of a novel botulinum neurotoxin gene cluster in enterococcus. FEBS Lett. 2018;592:310–317. doi: 10.1002/1873-3468.12969.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1873-3468.12969</ArticleId>
            <ArticleId IdType="pmc">PMC5838542</ArticleId>
            <ArticleId IdType="pubmed">29323697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caglič D, Krutein MC, Bompiani KM, et al.  Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain. J Med Chem. 2014;57:669–676. doi: 10.1021/jm4012164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm4012164</ArticleId>
            <ArticleId IdType="pmc">PMC3983388</ArticleId>
            <ArticleId IdType="pubmed">24387280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caleo M, Restani L. Direct central nervous system effects of botulinum neurotoxin. Toxicon. 2018;147:68–72. doi: 10.1016/j.toxicon.2017.10.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2017.10.027</ArticleId>
            <ArticleId IdType="pubmed">29111119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caleo M, Schiavo G. Central effects of tetanus and botulinum neurotoxins. Toxicon. 2009;54:593–599. doi: 10.1016/j.toxicon.2008.12.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2008.12.026</ArticleId>
            <ArticleId IdType="pubmed">19264088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caleo M, Spinelli M, Colosimo F, et al.  Transynaptic action of botulinum neurotoxin type A at central cholinergic boutons. J Neurosci. 2018;38:10329–10337. doi: 10.1523/jneurosci.0294-18.2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/jneurosci.0294-18.2018</ArticleId>
            <ArticleId IdType="pmc">PMC6596210</ArticleId>
            <ArticleId IdType="pubmed">30315128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type A formulations injected in the mouse leg. Muscle Nerve. 2009;40:374–380. doi: 10.1002/mus.21343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.21343</ArticleId>
            <ArticleId IdType="pubmed">19618426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CDC, Bioterrorism agents/diseases: https://emergency.cdc.gov/agent/agentlist-category.asp</Citation>
        </Reference>
        <Reference>
          <Citation>Cenciarelli O, Riley PW, Baka A. Biosecurity threat posed by botulinum toxin. Toxins. 2019;11:681. doi: 10.3390/toxins11120681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins11120681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S, Barbieri JT. Engineering botulinum neurotoxin to extend therapeutic intervention. Proc Natl Acad Sci USA. 2009;106:9180–9184. doi: 10.1073/pnas.0903111106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0903111106</ArticleId>
            <ArticleId IdType="pmc">PMC2695098</ArticleId>
            <ArticleId IdType="pubmed">19487672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C, Wang S, Wang H, et al.  Potent neutralization of botulinum neurotoxin/B by synergistic action of antibodies recognizing protein and ganglioside receptor binding domain. PLoS One. 2012;7(8):e43845–e43845. doi: 10.1371/journal.pone.0043845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0043845</ArticleId>
            <ArticleId IdType="pmc">PMC3430616</ArticleId>
            <ArticleId IdType="pubmed">22952786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol. 1992;31:677–679. doi: 10.1002/ana.410310619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410310619</ArticleId>
            <ArticleId IdType="pubmed">1514781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi JE, Werbel T, Wang Z, Wu CC, Yaksh TL, Di Nardo A. Botulinum toxin blocks mast cells and prevents rosacea like inflammation. J Dermatol Sci. 2019;93:58–64. doi: 10.1016/j.jdermsci.2018.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jdermsci.2018.12.004</ArticleId>
            <ArticleId IdType="pmc">PMC7680644</ArticleId>
            <ArticleId IdType="pubmed">30658871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choudhury S, Baker MR, Chatterjee S, Kumar H. Botulinum toxin: an update on pharmacology and newer products in development. Toxins. 2021;13:58. doi: 10.3390/toxins13010058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins13010058</ArticleId>
            <ArticleId IdType="pmc">PMC7828686</ArticleId>
            <ArticleId IdType="pubmed">33466571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colasante C, Rossetto O, Morbiato L, Pirazzini M, Molgó J, Montecucco C. Botulinum neurotoxin type A is internalized and translocated from small synaptic vesicles at the neuromuscular junction. Mol Neurobiol. 2013;48:120–127. doi: 10.1007/s12035-013-8423-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-013-8423-9</ArticleId>
            <ArticleId IdType="pubmed">23471747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Contreras E, Masuyer G, Qureshi N, et al.  A neurotoxin that specifically targets Anopheles mosquitoes. Nat Commun. 2019;10:2869. doi: 10.1038/s41467-019-10732-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-10732-w</ArticleId>
            <ArticleId IdType="pmc">PMC6599013</ArticleId>
            <ArticleId IdType="pubmed">31253776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Currà A, Trompetto C, Abbruzzese G, Berardelli A. Central effects of botulinum toxin type A: evidence and supposition. Mov Disord. 2004;19(Suppl 8):S60–S64. doi: 10.1002/mds.20011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.20011</ArticleId>
            <ArticleId IdType="pubmed">15027056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cutrer FM, Sandroni P, Wendelschafer-Crabb G. Botulinum toxin treatment of cephalalgia alopecia increases substance P and calcitonin gene-related peptide- containing cutaneous nerves in scalp. Cephalalgia. 2010;30:1000–1006. doi: 10.1111/j.1468-2982.2009.01987.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-2982.2009.01987.x</ArticleId>
            <ArticleId IdType="pubmed">19732078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Datta Gupta A, Edwards S, Smith J, et al.  Systematic review and meta-analysis of efficacy of botulinum toxin A for neuropathic pain. Toxins (basel) 2022;14:36. doi: 10.3390/toxins14010036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins14010036</ArticleId>
            <ArticleId IdType="pmc">PMC8780616</ArticleId>
            <ArticleId IdType="pubmed">35051013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Debaisieux S, Encheva V, Chakravarty P, Snijders AP, Schiavo G. Analysis of signaling endosome composition and dynamics using SILAC in embryonic stem cell-derived neurons. Mol Cell Proteomics. 2016;15:542–557. doi: 10.1074/mcp.M115.051649.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/mcp.M115.051649</ArticleId>
            <ArticleId IdType="pmc">PMC4739672</ArticleId>
            <ArticleId IdType="pubmed">26685126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deinhardt K, Salinas S, Verastegui C, Watson R, Worth D, Hanrahan S, Bucci C, Schiavo G. Rab5 and Rab7 control endocytic sorting along the axonal retrograde transport pathway. Neuron. 2006;52:293–305. doi: 10.1016/j.neuron.2006.08.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2006.08.018</ArticleId>
            <ArticleId IdType="pubmed">17046692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deppe J, Weisemann J, Mahrhold S, Rummel A. The 25 kDa HC-N domain of clostridial neurotoxins is indispensable for their neurotoxicity. Toxins. 2020;12:743. doi: 10.3390/toxins12120743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins12120743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolimbek BZ, Aoki KR, Steward LE, Jankovic L, Atassi MZ. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007;44:1029–1041. doi: 10.1016/j.molimm.2006.03.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molimm.2006.03.011</ArticleId>
            <ArticleId IdType="pubmed">16647121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong M, Masuyer G, Stenmark P. Botulinum and tetanus neurotoxins. Annu Rev Biochem. 2019;88:811–837. doi: 10.1146/annurev-biochem-013118-111654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-biochem-013118-111654</ArticleId>
            <ArticleId IdType="pmc">PMC7539302</ArticleId>
            <ArticleId IdType="pubmed">30388027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dover JS, Monheit G, Greener M, Pickett A. Botulinum toxin in aesthetic medicine: myths and realities. Dermatol Surg. 2018;44:249–260. doi: 10.1097/DSS.0000000000001277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/DSS.0000000000001277</ArticleId>
            <ArticleId IdType="pmc">PMC5821482</ArticleId>
            <ArticleId IdType="pubmed">29016535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doxey AC, Mansfield MJ, Montecucco C. Discovery of novel bacterial toxins by genomics and computational biology. Toxicon. 2018;147:2–12. doi: 10.1016/j.toxicon.2018.02.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2018.02.002</ArticleId>
            <ArticleId IdType="pubmed">29438679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol. 2003;49:34–38. doi: 10.1159/000067023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000067023</ArticleId>
            <ArticleId IdType="pubmed">12464716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco Different types of botulinum toxins in humans. Mov Disord. 2004;19:S53–S59. doi: 10.1002/mds.20010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.20010</ArticleId>
            <ArticleId IdType="pubmed">15027055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eleopra R, Montecucco C, Devigili G, et al.  Botulinum neurotoxin serotype D is poorly effective in humans: an in vivo electrophysiological study. Clin Neurophysiol. 2013;124:999–1004. doi: 10.1016/j.clinph.2012.11.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinph.2012.11.004</ArticleId>
            <ArticleId IdType="pubmed">23245668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>et Edgar RC, Taylor J, Lin V, et al.  Petabase-scale sequence alignment catalyses viral discovery. Nature. 2022;602:142–147. doi: 10.1038/s41586-021-04332-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-04332-2</ArticleId>
            <ArticleId IdType="pubmed">35082445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fenicia L, Anniballi F. Infant botulism. Ann Ist Super Sanita. 2009;45:134–146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19636165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finzi E, Wasserman E. Treatment of depression with botulinum toxin A: a case series. Dermatol Surg. 2006;32:645–649. doi: 10.1111/j.1524-4725.2006.32136.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1524-4725.2006.32136.x</ArticleId>
            <ArticleId IdType="pubmed">16706759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer A, Montal M. Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J Biol Chem. 2007;282:29604–29611. doi: 10.1074/jbc.M703619200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M703619200</ArticleId>
            <ArticleId IdType="pubmed">17666397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer A, Montal M. Molecular dissection of botulinum neurotoxin reveals interdomain chaperone function. Toxicon. 2013;75:101–107. doi: 10.1016/j.toxicon.2013.01.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2013.01.007</ArticleId>
            <ArticleId IdType="pmc">PMC3797153</ArticleId>
            <ArticleId IdType="pubmed">23396042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fleck-Derderian S, Shankar M, Rao AK, et al.  The epidemiology of foodborne botulism outbreaks: a systematic review. Clin Infect Dis. 2017;66:S73–S81. doi: 10.1093/cid/cix846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/cix846</ArticleId>
            <ArticleId IdType="pubmed">29293934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fogolari F, Tosatto SC, Muraro L, Montecucco C. Electric dipole reorientation in the interaction of botulinum neurotoxins with neuronal membranes. FEBS Lett. 2009;583:2321–2325. doi: 10.1016/j.febslet.2009.06.046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2009.06.046</ArticleId>
            <ArticleId IdType="pubmed">19576894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>França K, Lotti T. Botulinum toxin for the treatment of depression. Dermatol Ther. 2017 doi: 10.1111/dth.12422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dth.12422</ArticleId>
            <ArticleId IdType="pubmed">29272053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frank SP, Thon KP, Bischoff SC, Lorentz A. SNAP-23 and syntaxin-3 are required for chemokine release by mature human mast cells. Mol Immunol. 2011;49:353–358. doi: 10.1016/j.molimm.2011.09.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molimm.2011.09.011</ArticleId>
            <ArticleId IdType="pubmed">21981832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Rodriguez C, Levy R, Arndt J, et al.  Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol. 2007;25:107–116. doi: 10.1038/nbt1269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt1269</ArticleId>
            <ArticleId IdType="pubmed">17173035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Rodriguez C, Yan S, Isin N, et al.  A four-monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotypes C and D. Toxins. 2021;13:641. doi: 10.3390/toxins13090641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins13090641</ArticleId>
            <ArticleId IdType="pmc">PMC8472335</ArticleId>
            <ArticleId IdType="pubmed">34564645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gardner AP, Barbieri JT. Light chain diversity among the botulinum neurotoxins. Toxins. 2018;10:268. doi: 10.3390/toxins10070268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins10070268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garland M, Babin BM, Miyashita SI, et al.  Covalent modifiers of botulinum neurotoxin counteract toxin persistence. ACS Chem Biol. 2019;14:76–87. doi: 10.1021/acschembio.8b00937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acschembio.8b00937</ArticleId>
            <ArticleId IdType="pmc">PMC7204532</ArticleId>
            <ArticleId IdType="pubmed">30571080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gassner HG, Brissett AE, Otley CC, et al.  Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc. 2006;81:1023–1028. doi: 10.4065/81.8.1023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4065/81.8.1023</ArticleId>
            <ArticleId IdType="pubmed">16901024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghotloo S, Golsaz-Shirazi F, Amiri MM, Jeddi-Tehrani M, Shokri F. Epitope mapping of tetanus toxin by monoclonal antibodies: implication for immunotherapy and vaccine design. Neurotox Res. 2020;37:239–249. doi: 10.1007/s12640-019-00096-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12640-019-00096-w</ArticleId>
            <ArticleId IdType="pubmed">31410686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibbs KL, Kalmar B, Sleigh JN, Greensmith L, Schiavo G. In vivo imaging of axonal transport in murine motor and sensory neurons. J Neurosci Methods. 2016;257:26–33. doi: 10.1016/j.jneumeth.2015.09.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneumeth.2015.09.018</ArticleId>
            <ArticleId IdType="pmc">PMC4666412</ArticleId>
            <ArticleId IdType="pubmed">26424507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Go EJ, Ji J, Kim YH, Berta T, Park CK. Transient receptor potential channels and botulinum neurotoxins in chronic pain. Front Mol Neurosci. 2021;14:772719. doi: 10.3389/fnmol.2021.772719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2021.772719</ArticleId>
            <ArticleId IdType="pmc">PMC8586451</ArticleId>
            <ArticleId IdType="pubmed">34776867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grando SA, Zachary CB. The non-neuronal and nonmuscular effects of botulinum toxin: an opportunity for a deadly molecule to treat disease in the skin and beyond. Br J Dermatol. 2018;178:1011–1019. doi: 10.1111/bjd.16080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjd.16080</ArticleId>
            <ArticleId IdType="pubmed">29086923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grumelli C, Verderio C, Pozzi D, Rossetto O, Montecucco C, Matteoli M. Internalization and mechanism of action of clostridial toxins in neurons. Neurotoxicology. 2005;26:761–767. doi: 10.1016/j.neuro.2004.12.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuro.2004.12.012</ArticleId>
            <ArticleId IdType="pubmed">15925409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guida S, Farnetani F, Nisticò SP, et al.  New trends in botulinum toxin use in dermatology. Dermatol Pract Concept. 2018;8:277–282. doi: 10.5826/dpc.0804a05.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5826/dpc.0804a05</ArticleId>
            <ArticleId IdType="pmc">PMC6246063</ArticleId>
            <ArticleId IdType="pubmed">30479855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guidubaldi A, Fasano A, Ialongo T, et al.  Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Mov Disord. 2011;26:313–319. doi: 10.1002/mds.23473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.23473</ArticleId>
            <ArticleId IdType="pubmed">21259343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Habermann E. 125I-labeled neurotoxin from clostridium botulinum a: preparation, binding to synaptosomes and ascent to the spinal cord, naunyn-schmiedeberg's arch. Pharmacology. 1974;281:47–56.</Citation>
        </Reference>
        <Reference>
          <Citation>Hallett M, Albanese A, Dressler D, et al.  Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94–114. doi: 10.1016/j.toxicon.2012.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2012.12.004</ArticleId>
            <ArticleId IdType="pubmed">23380701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harper CB, Martin S, Nguyen TH, et al.  Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism. J Biol Chem. 2011;286:35966–35976. doi: 10.1074/jbc.M111.283879.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M111.283879</ArticleId>
            <ArticleId IdType="pmc">PMC3195592</ArticleId>
            <ArticleId IdType="pubmed">21832053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harper CB, Papadopulos A, Martin S, et al.  Botulinum neurotoxin type-A enters a non-recycling pool of synaptic vesicles. Sci Rep. 2016;6:19654. doi: 10.1038/srep19654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep19654</ArticleId>
            <ArticleId IdType="pmc">PMC4726273</ArticleId>
            <ArticleId IdType="pubmed">26805017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helton SG, Lohoff FW. Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders. Pharmacogenomics. 2015;16:541–553. doi: 10.2217/pgs.15.15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/pgs.15.15</ArticleId>
            <ArticleId IdType="pubmed">25916524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsieh LF, Wu CW, Chou CC, et al.  Effects of botulinum toxin landmark-guided intra-articular injection in subjects with knee osteoarthritis. PM R. 2016;8:1127–1135. doi: 10.1016/j.pmrj.2016.05.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pmrj.2016.05.009</ArticleId>
            <ArticleId IdType="pubmed">27210235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humphreys IR, Pei J, Baek M, et al.  Computed structures of core eukaryotic protein complexes. Science. 2021;374:eabm4805. doi: 10.1126/science.abm4805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abm4805</ArticleId>
            <ArticleId IdType="pmc">PMC7612107</ArticleId>
            <ArticleId IdType="pubmed">34762488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. J Am Med Ass. 2012;307:1736–1745. doi: 10.1001/jama.2012.505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2012.505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jahn R, Scheller RH. SNAREs-engines for membrane fusion. Nat Rev Mol Cell Biol. 2006;7:631–643. doi: 10.1038/nrm2002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2002</ArticleId>
            <ArticleId IdType="pubmed">16912714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jankovic J. Botulinum toxin: state of the art. Movement Disord. 2017;32:1131–1138. doi: 10.1002/mds.27072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.27072</ArticleId>
            <ArticleId IdType="pubmed">28639368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson EA, Montecucco C. Botulism. Handb Clin Neurol. 2008;91:333–368. doi: 10.1016/S0072-9752(07)01511-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0072-9752(07)01511-4</ArticleId>
            <ArticleId IdType="pubmed">18631849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jost WH, Benecke R, Hauschke D, et al.  Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Dev Ther. 2015;9:1913–1926. doi: 10.2147/dddt.s79193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/dddt.s79193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jumper J, Evans R, Pritzel A, et al.  Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–589. doi: 10.1038/s41586-021-03819-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03819-2</ArticleId>
            <ArticleId IdType="pmc">PMC8371605</ArticleId>
            <ArticleId IdType="pubmed">34265844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kabura L, Ilibagiza D, Menten J, Van den Ende J. Intrathecal vs intramuscular administration of human antitetanus immunoglobulin or equine tetanus antitoxin in the treatment of tetanus: a meta-analysis. Trop Med Int Health. 2006;11:1075–1081. doi: 10.1111/j.1365-3156.2006.01659.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-3156.2006.01659.x</ArticleId>
            <ArticleId IdType="pubmed">16827708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khenioui H, Houvenagel E, Catanzariti JF, Guyot MA, Agnani O, Donze C. Usefulness of intra-articular botulinum toxin injections. A systematic review. Joint Bone Spine. 2016;83:149–154. doi: 10.1016/j.jbspin.2015.10.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jbspin.2015.10.001</ArticleId>
            <ArticleId IdType="pubmed">26645160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim YS, Lee HJ, Cho SH, Lee JD, Kim HS. Early postoperative treatment of thyroidectomy scars using botulinum toxin: a split-scar, double-blind randomized controlled trial. Wound Repair Regen. 2014;22:605–612. doi: 10.1111/wrr.12204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/wrr.12204</ArticleId>
            <ArticleId IdType="pubmed">24898579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiris E, Burnett JC, Kane CD, Bavari S. Recent advances in botulinum neurotoxin inhibitor development. Curr Top Med Chem. 2014;14:2044–2061. doi: 10.2174/1568026614666141022093350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1568026614666141022093350</ArticleId>
            <ArticleId IdType="pubmed">25335887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar G, Agarwal R, Swaminathan S. Small molecule non-peptide inhibitors of botulinum neurotoxin serotype E: structure–activity relationship and a pharmacophore model. Bioorg Med Chem. 2016;24:3978–3985. doi: 10.1016/j.bmc.2016.06.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bmc.2016.06.036</ArticleId>
            <ArticleId IdType="pubmed">27353886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lam KH, Guo Z, Krez N, et al.  A viral-fusion-peptide-like molecular switch drives membrane insertion of botulinum neurotoxin A1. Nat Comm. 2018;9:5367. doi: 10.1038/s41467-018-07789-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-07789-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lam KH, Tremblay JM, Vazquez-Cintron E, et al.  Structural insights into rational design of single-domain antibody-based antitoxins against botulinum neurotoxins. Cell Rep. 2020;30:2526–2539.e6. doi: 10.1016/j.celrep.2020.01.107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2020.01.107</ArticleId>
            <ArticleId IdType="pmc">PMC7138525</ArticleId>
            <ArticleId IdType="pubmed">32101733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawrence GW, Foran P, Oliver Dolly J. Insights into a basis for incomplete inhibition by botulinum toxin A of Ca2+-evoked exocytosis from permeabilised chromaffin cells. Toxicology. 2002;181–182:249–253. doi: 10.1016/s0300-483x(02)00453-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0300-483x(02)00453-5</ArticleId>
            <ArticleId IdType="pubmed">12505320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li B, Peet NP, Butler MM, Burnett JC, Moir DT, Bowlin TL. Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication. Molecules. 2010;16:202–220. doi: 10.3390/molecules16010202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/molecules16010202</ArticleId>
            <ArticleId IdType="pmc">PMC6259422</ArticleId>
            <ArticleId IdType="pubmed">21193845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li ZJ, Park SB, Sohn KC, et al.  Regulation of lipid production by acetylcholine signalling in human sebaceous glands. J Dermatol Sci. 2013;72:116–122. doi: 10.1016/j.jdermsci.2013.06.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jdermsci.2013.06.009</ArticleId>
            <ArticleId IdType="pubmed">23849311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Liu T, Luo W. Botulinum neurotoxin therapy for depression: therapeutic mechanisms and future perspective. Front Psychiatry. 2021;12:584416. doi: 10.3389/fpsyt.2021.584416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fpsyt.2021.584416</ArticleId>
            <ArticleId IdType="pmc">PMC8102733</ArticleId>
            <ArticleId IdType="pubmed">33967844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin L, Olson ME, Eubanks LM, Janda KD. Strategies to counteract botulinum neurotoxin A: nature’s deadliest biomolecule. Acc Chem Res. 2019;52:2322–2331. doi: 10.1021/acs.accounts.9b00261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.accounts.9b00261</ArticleId>
            <ArticleId IdType="pmc">PMC7478247</ArticleId>
            <ArticleId IdType="pubmed">31322847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin L, Olson ME, Sugane T, et al.  Catch and anchor approach to combat both toxicity and longevity of botulinum toxin A. J Med Chem. 2020;63:11100–11120. doi: 10.1021/acs.jmedchem.0c01006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jmedchem.0c01006</ArticleId>
            <ArticleId IdType="pmc">PMC7581224</ArticleId>
            <ArticleId IdType="pubmed">32886509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin L, Turner LD, Šilhár P, Pellett S, Johnson EA, Janda KD. Identification of 3-hydroxy-1,2-dimethylpyridine-4(1H)-thione as a metal-binding motif for the inhibition of botulinum neurotoxin A. RSC Med Chem. 2021;12:137–143. doi: 10.1039/D0MD00320D.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/D0MD00320D</ArticleId>
            <ArticleId IdType="pmc">PMC8130615</ArticleId>
            <ArticleId IdType="pubmed">34046606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magid M, Reichenberg JS, Poth PE, et al.  Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75:837–844. doi: 10.4088/JCP.13m08845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4088/JCP.13m08845</ArticleId>
            <ArticleId IdType="pubmed">24910934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magid M, Keeling BH, Reichenberg JS. Neurotoxins: expanding uses of neuromodulators in medicine-major depressive disorder. Plast Reconstr Surg. 2015;136:111S–119S. doi: 10.1097/PRS.0000000000001733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PRS.0000000000001733</ArticleId>
            <ArticleId IdType="pubmed">26441090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maiarù M, Leese C, Certo M, et al.  Selective neuronal silencing using synthetic botulinum molecules alleviates chronic pain in mice. Sci Transl Med. 2018;10:eaar7384. doi: 10.1126/scitranslmed.aar7384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aar7384</ArticleId>
            <ArticleId IdType="pubmed">30021888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mansfield MJ, Adams JB, Doxey AC. Botulinum neurotoxin homologs in non-Clostridium species. FEBS Lett. 2015;589:342–348. doi: 10.1016/j.febslet.2014.12.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2014.12.018</ArticleId>
            <ArticleId IdType="pubmed">25541486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mansfield MJ, Wentz TG, Zhang S, et al.  Bioinformatic discovery of a toxin family in Chryseobacterium piperi with sequence similarity to botulinum neurotoxins. Sci Rep. 2019;9:1634. doi: 10.1038/s41598-018-37647-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-37647-8</ArticleId>
            <ArticleId IdType="pmc">PMC6367388</ArticleId>
            <ArticleId IdType="pubmed">30733520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marinelli S, Vacca V, Ricordy R, et al.  The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes. PLoS One. 2012;7:e47977. doi: 10.1371/journal.pone.0047977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0047977</ArticleId>
            <ArticleId IdType="pmc">PMC3480491</ArticleId>
            <ArticleId IdType="pubmed">23110146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marlow M, Edwards L, McCrickard L, et al.  Mild botulism from illicitly brewed alcohol in a large prison outbreak in mississippi. Front Publ Health. 2021 doi: 10.3389/fpubh.2021.716615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fpubh.2021.716615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martina E, Diotallevi F, Radi G, Campanati A, Offidani A. Therapeutic use of botulinum neurotoxins in dermatology: systematic review. Toxins. 2021;13:120. doi: 10.3390/toxins13020120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins13020120</ArticleId>
            <ArticleId IdType="pmc">PMC7915854</ArticleId>
            <ArticleId IdType="pubmed">33562846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin-Martin B, Nabokina SM, Blasi J, Lazo PA, Molined F. Involvement of SNAP-23 and syntaxin 6 in human neutrophil exocytosis. Blood. 2000;96:2574–2583. doi: 10.1182/blood.V96.7.2574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.V96.7.2574</ArticleId>
            <ArticleId IdType="pubmed">11001914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masaki C, Sharpley AL, Godlewska BR, et al.  Effects of the potential Lithium-mimetic, ebselen, on brain neurochemistry: a magnetic resonance study. Psychopharmacology. 2016;233:2655–2661. doi: 10.1007/s00213-016-4319-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-016-4319-5</ArticleId>
            <ArticleId IdType="pmc">PMC4917572</ArticleId>
            <ArticleId IdType="pubmed">27256357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masaki C, Sharpley AL, Cooper CM, et al.  Effects of the potential lithium-mimetic, ebselen, on impulsivity and emotional processing. Psychopharmacology. 2016;233:1097–1104. doi: 10.1007/s00213-015-4189-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-015-4189-2</ArticleId>
            <ArticleId IdType="pmc">PMC4759215</ArticleId>
            <ArticleId IdType="pubmed">26758281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maslanka SE, Luquez C, Dykes JK, et al.  A novel botulinum toxin, previously reported as serotype H, has a hybrid structure of known serotypes A and F that is neutralized with serotype A antitoxin. J Infect Dis. 2015;213:379–385. doi: 10.1093/infdis/jiv327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jiv327</ArticleId>
            <ArticleId IdType="pmc">PMC4704661</ArticleId>
            <ArticleId IdType="pubmed">26068781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masuyer G, Chaddock JA, Foster KA, Acharya KR. Engineered botulinum neurotoxins as new therapeutics. Annu Rev Pharmacol Toxicol. 2014;54:27–51. doi: 10.1146/annurev-pharmtox-011613-135935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-pharmtox-011613-135935</ArticleId>
            <ArticleId IdType="pubmed">24016211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matak I, Bach-Rojecky L, Filipovic B, Lackovic Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience. 2011;186:201–207. doi: 10.1016/j.neuroscience.2011.04.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2011.04.026</ArticleId>
            <ArticleId IdType="pubmed">21539899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matak I, Riederer P, Lacković Z. Botulinum toxin's axonal transport from periphery to the spinal cord. Neurochem Int. 2012;61:236–239. doi: 10.1016/j.neuint.2012.05.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuint.2012.05.001</ArticleId>
            <ArticleId IdType="pubmed">22580329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matak I, Rossetto O, Lacković Z. Botulinum toxin type A selectivity for certain types of pain is associated with capsaicin-sensitive neurons. Pain. 2014;155:1516–1526. doi: 10.1016/j.pain.2014.04.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pain.2014.04.027</ArticleId>
            <ArticleId IdType="pubmed">24793910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matteoli M, Verderio C, Rossetto,, et al.  Synaptic vesicle endocytosis mediates the entry of tetanus neurotoxin into hippocampal neurons. Proc Natl Acad Sci USA. 1996;93:13310–13315. doi: 10.1073/pnas.93.23.13310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.93.23.13310</ArticleId>
            <ArticleId IdType="pmc">PMC24089</ArticleId>
            <ArticleId IdType="pubmed">8917587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazzocchio R, Caleo M. More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system. Neuroscientist. 2015;21:44–61. doi: 10.1177/1073858414524633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1073858414524633</ArticleId>
            <ArticleId IdType="pubmed">24576870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McNutt PM, Vazquez-Cintron EJ, Tenezaca L, et al.  Neuronal delivery of antibodies has therapeutic effects in animal models of botulism. Science Transl Med. 2021;13:575. doi: 10.1126/scitranslmed.abd7789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.abd7789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Megighian A, Scorzeto M, Zanini D, et al.  Arg206 of SNAP-25 is essential for neuroexocytosis at the Drosophila melanogaster neuromuscular junction. J Cell Sci. 2010;123:3276–3283. doi: 10.1242/jcs.071316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.071316</ArticleId>
            <ArticleId IdType="pubmed">20826463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Megighian A, Pirazzini M, Fabris F, Rossetto O, Montecucco C. TETANUS and TETANUS NEUROTOXIN: from peripheral uptake to central nervous tissue targets. J Neurochem. 2021;158:1244–1253. doi: 10.1111/jnc.15330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.15330</ArticleId>
            <ArticleId IdType="pubmed">33629408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melo DF, Ramos PM, Antelo DAP, et al.  Is there a rationale for the use of botulinum toxin in the treatment of Androgenetic Alopecia? J Cosmet Dermatol. 2021;20:2093–2095. doi: 10.1111/jocd.14177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jocd.14177</ArticleId>
            <ArticleId IdType="pubmed">33894053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minamitani T, Kiyose K, Otsubo R, et al.  Novel neutralizing human monoclonal antibodies against tetanus neurotoxin. Sci Rep. 2021;11:12134. doi: 10.1038/s41598-021-91597-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-021-91597-2</ArticleId>
            <ArticleId IdType="pmc">PMC8190289</ArticleId>
            <ArticleId IdType="pubmed">34108521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyashita SI, Zhang J, Zhang S, Shoemaker CB, Dong M. Delivery of single-domain antibodies into neurons using a chimeric toxin-based platform is therapeutic in mouse models of botulism. Sci Transl Med. 2021;13:575. doi: 10.1126/scitranslmed.aaz4197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aaz4197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molgo J, Lemeignan M, Thesleff S. Aminoglycosides and 3, 4-diaminopyridine on neuromuscular block caused by botulinum type A toxin. Muscle Nerve. 1987;10:464–470. doi: 10.1002/mus.880100514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.880100514</ArticleId>
            <ArticleId IdType="pubmed">3497343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montal M. Redox regulation of botulinum neurotoxin toxicity: therapeutic implications. Trends Mol Med. 2014;20:602–603. doi: 10.1016/j.molmed.2014.09.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmed.2014.09.005</ArticleId>
            <ArticleId IdType="pmc">PMC4253726</ArticleId>
            <ArticleId IdType="pubmed">25242227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montecucco C, Rasotto MB. On Botulinum neurotoxin variability. Mbio. 2015;6:e02131–e2214. doi: 10.1128/mBio.02131-14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mBio.02131-14</ArticleId>
            <ArticleId IdType="pmc">PMC4313909</ArticleId>
            <ArticleId IdType="pubmed">25564463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montecucco C, Zanotti G. Botulinum neurotoxin A1 likes it double sweet. Nat Struct Mol Biol. 2016;23:619–621. doi: 10.1038/nsmb.3253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nsmb.3253</ArticleId>
            <ArticleId IdType="pubmed">27384187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montecucco C, Schiavo G, Pantano S. SNARE complexes and neuroexocytosis: how many, how close? Trends Biochem Sci. 2005;30:367–372. doi: 10.1016/j.tibs.2005.05.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tibs.2005.05.002</ArticleId>
            <ArticleId IdType="pubmed">15935678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morra ME, Elgebaly A, Elmaraezy A, et al.  Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2016;1:63. doi: 10.1186/s10194-016-0651-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s10194-016-0651-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mukherjee J, Tremblay JM, Leysath CE, Ofori K, Baldwin K, Feng X, et al.  A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS One. 2012;7:e29941. doi: 10.1371/journal.pone.0029941.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0029941</ArticleId>
            <ArticleId IdType="pmc">PMC3253120</ArticleId>
            <ArticleId IdType="pubmed">22238680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muraro L, Tosatto S, Motterlini L, Rossetto O, Montecucco C. The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane. Biochem Biophys Res Commun. 2009;380:76–80. doi: 10.1016/j.bbrc.2009.01.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2009.01.037</ArticleId>
            <ArticleId IdType="pubmed">19161982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naik PP. Utilities of botulinum toxins in dermatology and cosmetology. Clin Cosmet Investig Dermatol. 2021;14:1319–1330. doi: 10.2147/CCID.S332247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CCID.S332247</ArticleId>
            <ArticleId IdType="pmc">PMC8464334</ArticleId>
            <ArticleId IdType="pubmed">34584436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogawa A, Yoshimoto T, Kikuchi H, et al.  Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial. Cerebrovasc Dis. 1999;9:112–118. doi: 10.1159/000015908.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000015908</ArticleId>
            <ArticleId IdType="pubmed">9973655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pantano S, Montecucco C. The blockade of the neurotransmitter release apparatus by botulinum neurotoxins. Cell Mol Life Sci. 2014;71:793–811. doi: 10.1007/s00018-013-1380-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-013-1380-7</ArticleId>
            <ArticleId IdType="pubmed">23749048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pappas G, Kiriaze IJ, Falagas ME. Insights into infectious disease in the era of Hippocrates. Int J Infect Dis. 2008;12:347–350. doi: 10.1016/j.ijid.2007.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijid.2007.11.003</ArticleId>
            <ArticleId IdType="pubmed">18178502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel KB, Cai S, Adler M, Singh BK, Parmar VS, Singh BR. Natural compounds and their analogues as potent antidotes against the most poisonous bacterial toxin. Appl Environ Microbiol. 2018;84:e01280–e1318. doi: 10.1128/AEM.01280-18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AEM.01280-18</ArticleId>
            <ArticleId IdType="pmc">PMC6275346</ArticleId>
            <ArticleId IdType="pubmed">30389764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peck MW, Smith TJ, Anniballi F, et al.  Historical perspectives and guidelines for botulinum neurotoxin subtype nomenclature. Toxins. 2017;9:38. doi: 10.3390/toxins9010038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins9010038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirazzini M, Rossetto O. Challenges in searching for therapeutics against botulinum neurotoxins. Expert Opin Drug Discov. 2017;12:497–510. doi: 10.1080/17460441.2017.1303476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/17460441.2017.1303476</ArticleId>
            <ArticleId IdType="pubmed">28271909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirazzini M, Bordin F, Rossetto O, Shone CC, Binz T, Montecucco C. The thioredoxin reductase-thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals. FEBS Lett. 2013;587:150–155. doi: 10.1016/j.febslet.2012.11.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2012.11.007</ArticleId>
            <ArticleId IdType="pubmed">23178719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirazzini M, Henke T, Rossetto O, et al.  Neutralisation of specific surface carboxylates speeds up translocation of botulinum neurotoxin type B enzymatic domain. FEBS Lett. 2013;587:3831–3836. doi: 10.1016/j.febslet.2013.10.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2013.10.010</ArticleId>
            <ArticleId IdType="pubmed">24157364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirazzini M, Azarnia Tehran D, Zanetti G, et al.  Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins. Cell Rep. 2014;8:1870–1878. doi: 10.1016/j.celrep.2014.08.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2014.08.017</ArticleId>
            <ArticleId IdType="pubmed">25220457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirazzini M, Azarnia Tehran D, Zanetti G, et al.  The thioredoxin reductase–Thioredoxin redox system cleaves the interchain disulphide bond of botulinum neurotoxins on the cytosolic surface of synaptic vesicles. Toxicon. 2015;107:32–36. doi: 10.1016/j.toxicon.2015.06.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2015.06.019</ArticleId>
            <ArticleId IdType="pubmed">26130523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirazzini M, Tehran DA, Leka O, Zanetti G, Rossetto O, Montecucco C. On the translocation of botulinum and tetanus neurotoxins across the membrane of acidic intracellular compartments. Biochim Biophys Acta. 2015 doi: 10.1016/j.bbamem.2015.08.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamem.2015.08.014</ArticleId>
            <ArticleId IdType="pubmed">26307528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69:200–235. doi: 10.1124/pr.116.012658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/pr.116.012658</ArticleId>
            <ArticleId IdType="pmc">PMC5394922</ArticleId>
            <ArticleId IdType="pubmed">28356439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirazzini M, Azarnia Tehran D, Zanetti G, Rossetto O, Montecucco C. Hsp90 and thioredoxin-thioredoxin Reductase enable the catalytic activity of Clostridial neurotoxins inside nerve terminals. Toxicon. 2018;147:32–37. doi: 10.1016/j.toxicon.2017.10.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2017.10.028</ArticleId>
            <ArticleId IdType="pubmed">29111118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirazzini M, Grinzato A, Corti D, et al.  Exceptionally potent human monoclonal antibodies are effective for prophylaxis and therapy of tetanus in mice. J Clin Invest. 2021;131:e151676. doi: 10.1172/JCI151676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI151676</ArticleId>
            <ArticleId IdType="pmc">PMC8592554</ArticleId>
            <ArticleId IdType="pubmed">34618682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pons L, Vilain C, Volteau M, Picaut P. Safety and pharmacodynamics of a novel recombinant botulinum toxin E (rBoNT-E): Results of a phase 1 study in healthy male subjects compared with abobotulinumtoxinA (Dysport®) J Neurol Sci. 2019;407:116516. doi: 10.1016/j.jns.2019.116516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2019.116516</ArticleId>
            <ArticleId IdType="pubmed">31655410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prinetti A, Loberto N, Chigorno V, Sonnino S. Glycosphingolipid behaviour in complex membranes. Biochim Biophys Acta. 2009;1788:184–193. doi: 10.1016/j.bbamem.2008.09.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamem.2008.09.001</ArticleId>
            <ArticleId IdType="pubmed">18835549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian H, Shao F, Lenahan C, Shao A, Li Y. Efficacy and safety of botulinum toxin vs. placebo in depression: a systematic review and meta-analysis of randomized controlled trials. Front Psychiatry. 2020;11:603087. doi: 10.3389/fpsyt.2020.603087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fpsyt.2020.603087</ArticleId>
            <ArticleId IdType="pmc">PMC7746677</ArticleId>
            <ArticleId IdType="pubmed">33343429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao AK, Sobel J, Chatham-Stephens K, Luquez C (2021) Clinical guidelines for diagnosis and treatment of botulism. MMWR Recommendations Rep 70:1–30. 10.15585/mmwr.rr7002a1https://www.cdc.gov/mmwr/volumes/70/rr/rr7002a1.htm</Citation>
        </Reference>
        <Reference>
          <Citation>Rasetti-Escargueil C, Popoff MR. Antibodies and vaccines against botulinum toxins: available measures and novel approaches. Toxins. 2019;11:528. doi: 10.3390/toxins11090528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins11090528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Restani L, Giribaldi F, Manich M, et al.  Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog. 2012;8:e1003087. doi: 10.1371/journal.ppat.1003087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1003087</ArticleId>
            <ArticleId IdType="pmc">PMC3531519</ArticleId>
            <ArticleId IdType="pubmed">23300443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rezasoltani Z, Dadarkhah A, Tabatabaee SM, et al.  Therapeutic effects of intra-articular botulinum neurotoxin versus physical therapy in knee osteoarthritis. Anesth Pain Med. 2021;11:e112789. doi: 10.5812/aapm.112789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5812/aapm.112789</ArticleId>
            <ArticleId IdType="pmc">PMC8438713</ArticleId>
            <ArticleId IdType="pubmed">34540630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ri S, Kivi A, Wissel J. The safety and effect of local botulinum toxin A injections for long-term management of chronic pain in post-herpetic neuralgia: literature review and cases report treated with incobotulinumtoxin A. J Pers Med. 2021;11:758. doi: 10.3390/jpm11080758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jpm11080758</ArticleId>
            <ArticleId IdType="pmc">PMC8400134</ArticleId>
            <ArticleId IdType="pubmed">34442402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rose AE, Goldberg DJ. Safety and efficacy of intradermal injection of botulinum toxin for the treatment of oily skin. Dermatol Surg. 2013;39:443–448. doi: 10.1111/dsu.12097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dsu.12097</ArticleId>
            <ArticleId IdType="pubmed">23293895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossetto O, Montecucco C. Tables of toxicity of botulinum and tetanus neurotoxins. Toxins. 2019 doi: 10.3390/toxins11120686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins11120686</ArticleId>
            <ArticleId IdType="pmc">PMC6950492</ArticleId>
            <ArticleId IdType="pubmed">31771110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12:535–549. doi: 10.1038/nrmicro3295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrmicro3295</ArticleId>
            <ArticleId IdType="pubmed">24975322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossetto O, Pirazzini M, Lista F, Montecucco C. The role of the single interchains disulfide bond in tetanus and botulinum neurotoxins and the development of antitetanus and antibotulism drugs. Cell Microbiol. 2019 doi: 10.1111/cmi.13037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cmi.13037</ArticleId>
            <ArticleId IdType="pmc">PMC6899712</ArticleId>
            <ArticleId IdType="pubmed">31050145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossetto O, Pirazzini M, Lista F, Montecucco C. The role of the single interchain disulfide bond in tetanus and botulinum neurotoxins and the development of antitetanus and antibotulism drugs. Cell Microbiol. 2019;21:e13037. doi: 10.1111/cmi.13037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cmi.13037</ArticleId>
            <ArticleId IdType="pmc">PMC6899712</ArticleId>
            <ArticleId IdType="pubmed">31050145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rummel A. The long journey of botulinum neurotoxins into the synapse. Toxicon. 2015;107:9–24. doi: 10.1016/j.toxicon.2015.09.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2015.09.009</ArticleId>
            <ArticleId IdType="pubmed">26363288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 1992;56:80–99. doi: 10.1128/mr.56.1.80-99.1992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mr.56.1.80-99.1992</ArticleId>
            <ArticleId IdType="pmc">PMC372855</ArticleId>
            <ArticleId IdType="pubmed">1579114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiavo G, Benfenati F, Poulain B, et al.  Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature. 1992;359:832–835. doi: 10.1038/359832a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/359832a0</ArticleId>
            <ArticleId IdType="pubmed">1331807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiavo G, Poulain B, Rossetto O, Benfenati F, Tauc L, Montecucco C. Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc. EMBO J. 1992;11:3577–3583. doi: 10.1002/j.1460-2075.1992.tb05441.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/j.1460-2075.1992.tb05441.x</ArticleId>
            <ArticleId IdType="pmc">PMC556816</ArticleId>
            <ArticleId IdType="pubmed">1396558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiavo G, Santucci A, Dasgupta BR, et al.  Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett. 1993;335:99–103. doi: 10.1016/0014-5793(93)80448-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0014-5793(93)80448-4</ArticleId>
            <ArticleId IdType="pubmed">8243676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmieg N, Menendez G, Schiavo G, Terenzio M. Signalling endosomes in axonal transport: travel updates on the molecular highway. Sem Cell Dev Biol. 2014;27:32–43. doi: 10.1016/j.semcdb.2013.10.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcdb.2013.10.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulze J, Neumann I, Magid M, et al.  Botulinum toxin for the management of depression: an updated review of the evidence and meta-analysis. J Psychiatr Res. 2021;135:332–340. doi: 10.1016/j.jpsychires.2021.01.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpsychires.2021.01.016</ArticleId>
            <ArticleId IdType="pubmed">33578275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044–1049. doi: 10.1016/S0161-6420(80)35127-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0161-6420(80)35127-0</ArticleId>
            <ArticleId IdType="pubmed">7243198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12:924–927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4203467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sen E, Kota KP, Panchal RG, Bavari S, Kiris E. Screening of a focused ubiquitin-proteasome pathway inhibitor library identifies small molecules as novel modulators of botulinum neurotoxin type A toxicity. Front Pharmacol. 2021 doi: 10.3389/fphar.2021.763950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2021.763950</ArticleId>
            <ArticleId IdType="pmc">PMC8666879</ArticleId>
            <ArticleId IdType="pubmed">34912220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharpley A, Williams C, Holder AA, et al.  A phase 2a randomized, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania and hypomania. Psychopharmacology. 2020;237:3773–3782. doi: 10.1007/s00213-020-05654-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00213-020-05654-1</ArticleId>
            <ArticleId IdType="pmc">PMC7683468</ArticleId>
            <ArticleId IdType="pubmed">32909076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shuo L, Ting Y, KeLun W, Rui Z, Rui Z, Hang W. Efficacy and possible mechanisms of botulinum toxin treatment of oily skin. J Cosmet Dermatol. 2019;18:451–457. doi: 10.1111/jocd.12866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jocd.12866</ArticleId>
            <ArticleId IdType="pubmed">30697928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel LS, Johnson-Winegar AD, Sellin LC. Effect of 3,4-diaminopyridine on the survival of mice injected with botulinum neurotoxin type A, B, E, or F. Toxicol Appl Pharmacol. 1986;84:255–263. doi: 10.1016/0041-008x(86)90133-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0041-008x(86)90133-x</ArticleId>
            <ArticleId IdType="pubmed">3715874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sikorra S, Donald S, Elliot M, et al.  Engineering an effective human SNAP-23 cleaving botulinum neurotoxin A variant. Toxins. 2021;12:804. doi: 10.3390/toxins12120804.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins12120804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000;1:31–39. doi: 10.1038/35036052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35036052</ArticleId>
            <ArticleId IdType="pubmed">11413487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson LL. A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism. Infect Immun. 1986;52:858–862. doi: 10.1128/iai.52.3.858-862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/iai.52.3.858-862</ArticleId>
            <ArticleId IdType="pmc">PMC260939</ArticleId>
            <ArticleId IdType="pubmed">3011675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh N, Halliday AC, Thomas JM, et al.  A safe lithium mimetic for bipolar disorder. Nat Commun. 2013;4:1332. doi: 10.1038/ncomms2320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms2320</ArticleId>
            <ArticleId IdType="pmc">PMC3605789</ArticleId>
            <ArticleId IdType="pubmed">23299882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh N, Sharpley AL, Emir UE, et al.  Effect of the putative lithium mimetic Ebselen on brain Myo-Inositol, sleep, and emotional processing in humans. Neuropsychopharmacology. 2016;41:1768–1778. doi: 10.1038/npp.2015.343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/npp.2015.343</ArticleId>
            <ArticleId IdType="pmc">PMC4770517</ArticleId>
            <ArticleId IdType="pubmed">26593266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sleigh JN, Rossor AM, Fellows AD, Tosolini AP, Schiavo G. Axonal transport and neurological disease. Nat Rev Neurol. 2019;15:691–703. doi: 10.1038/s41582-019-0257-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41582-019-0257-2</ArticleId>
            <ArticleId IdType="pubmed">31558780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sleigh JN, Tosolini AP, Schiavo G. In vivo imaging of anterograde and retrograde axonal transport in rodent peripheral nerves. Methods Mol Biol. 2020;2143:271–292. doi: 10.1007/978-1-0716-0585-1_20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-0716-0585-1_20</ArticleId>
            <ArticleId IdType="pmc">PMC7116510</ArticleId>
            <ArticleId IdType="pubmed">32524487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith TJ, Lou J, Geren IN, et al.  Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun. 2005;73:5450–5457. doi: 10.1128/IAI.73.9.5450-5457.2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.73.9.5450-5457.2005</ArticleId>
            <ArticleId IdType="pmc">PMC1231122</ArticleId>
            <ArticleId IdType="pubmed">16113261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snow DM, Riling K, Kimbler A, et al.  Safety and pharmacokinetics of a four monoclonal antibody combination against botulinum C and D neurotoxins. Antimicrob Agents Chemother. 2019;63:e01270–e1319. doi: 10.1128/AAC.01270-19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.01270-19</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sobel J. Botulism. Clin Infect Dis. 2005;41:1167–1173. doi: 10.1086/444507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/444507</ArticleId>
            <ArticleId IdType="pubmed">16163636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sohrabi C, Goutos I. The use of botulinum toxin in keloid scar management: a literature review. Scars Burn Heal. 2020;6:2059513120926628. doi: 10.1177/2059513120926628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2059513120926628</ArticleId>
            <ArticleId IdType="pmc">PMC7323272</ArticleId>
            <ArticleId IdType="pubmed">32637157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Surana S, Tosolini AP, Meyer IFG, et al.  The travel diaries of tetanus and botulinum neurotoxins. Toxicon. 2018;147:58–67. doi: 10.1016/j.toxicon.2017.10.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2017.10.008</ArticleId>
            <ArticleId IdType="pubmed">29031941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talbet JH, Elnahry AG. OnabotulinumtoxinA for the treatment of headache: an updated review. J Integr Neurosci. 2022;21:37. doi: 10.31083/j.jin2101037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.31083/j.jin2101037</ArticleId>
            <ArticleId IdType="pubmed">35164473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao L, Peng L, Berntsson RPA, et al.  Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors. Nat Commun. 2017;8:53. doi: 10.1038/s41467-017-00064-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-00064-y</ArticleId>
            <ArticleId IdType="pmc">PMC5495808</ArticleId>
            <ArticleId IdType="pubmed">28674381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tehran DA, Pirazzini M. Novel botulinum neurotoxins: exploring underneath the iceberg tip. Toxins. 2018 doi: 10.3390/toxins10050190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins10050190</ArticleId>
            <ArticleId IdType="pmc">PMC5983246</ArticleId>
            <ArticleId IdType="pubmed">29748471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thaker H, Zhang J, Miyashita SI, et al.  Knockin mouse models demonstrate differential contributions of synaptotagmin-1 and -2 as receptors for botulinum neurotoxins. PLoS Pathog. 2021;17:e1009994. doi: 10.1371/journal.ppat.1009994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1009994</ArticleId>
            <ArticleId IdType="pmc">PMC8553082</ArticleId>
            <ArticleId IdType="pubmed">34662366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomic MT, Farr-Jones S, Syar ES, et al.  Neutralizing concentrations of anti-botulinum toxin antibodies positively correlate with mouse neutralization assay results in a guinea pig model. Toxins. 2021;13:671. doi: 10.3390/toxins13090671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins13090671</ArticleId>
            <ArticleId IdType="pmc">PMC8471557</ArticleId>
            <ArticleId IdType="pubmed">34564675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai YC, Maditz R, Kuo C-l, et al.  Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci USA. 2010;107:16554–16559. doi: 10.1073/pnas.1008302107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1008302107</ArticleId>
            <ArticleId IdType="pmc">PMC2944746</ArticleId>
            <ArticleId IdType="pubmed">20823219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai YC, Kotiya A, Kiris E, et al.  Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication. Proc Natl Acad Sci USA. 2017;114:E5158. doi: 10.1073/pnas.1621076114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1621076114</ArticleId>
            <ArticleId IdType="pmc">PMC5495235</ArticleId>
            <ArticleId IdType="pubmed">28584101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tunyasuvunakool K, Adler J, Wu Z, et al.  Highly accurate protein structure prediction for the human proteome. Nature. 2021;596:590–596. doi: 10.1038/s41586-021-03828-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03828-1</ArticleId>
            <ArticleId IdType="pmc">PMC8387240</ArticleId>
            <ArticleId IdType="pubmed">34293799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner LD, Nielsen AL, Lin L, et al.  Use of crystallography and molecular modeling for the inhibition of the botulinum neurotoxin A protease. ACS Med Chem Lett. 2021;12:1318–1324. doi: 10.1021/acsmedchemlett.1c00325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsmedchemlett.1c00325</ArticleId>
            <ArticleId IdType="pmc">PMC8365998</ArticleId>
            <ArticleId IdType="pubmed">34413962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner LD, Nielsen AL, Lin L, et al.  Irreversible inhibition of BoNT/A protease: proximity-driven reactivity contingent upon a bifunctional approach. RSC Med Chem. 2021;12:960–969. doi: 10.1039/d1md00089f.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/d1md00089f</ArticleId>
            <ArticleId IdType="pmc">PMC8221255</ArticleId>
            <ArticleId IdType="pubmed">34223161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vazquez-Cintron E, Machamer J, Ondeck C, et al.  Symptomatic treatment of botulism with a clinically approved small molecule. J Clin Inv Insight. 2020;5:e132891. doi: 10.1172/jci.insight.132891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.132891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vieni C, McGillick B, Kumaran D, Eswaramoorthy E, Kandavelu P, et al.  Structure based discovery of pan active botulinum neurotoxin inhibitors. J Infect Dis Ther. 2018;6:351. doi: 10.4172/2332-0877.1000351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4172/2332-0877.1000351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villar RG, Elliott SP, Davenport KM. Botulism: the many faces of botulinum toxin and its potential for bioterrorism. Infect Dis Clin North Am. 2006;20:313–327. doi: 10.1016/j.idc.2006.02.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.idc.2006.02.003</ArticleId>
            <ArticleId IdType="pubmed">16762741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T, Martin S, Papadopulos A, et al.  Control of autophagosome axonal retrograde flux by presynaptic activity unveiled using botulinum neurotoxin type A. J Neurosci. 2015;35:6179–6194. doi: 10.1523/jneurosci.3757-14.2015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/jneurosci.3757-14.2015</ArticleId>
            <ArticleId IdType="pmc">PMC4787026</ArticleId>
            <ArticleId IdType="pubmed">25878289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Yu R, Fang T, et al.  Tetanus neurotoxin neutralizing antibodies screened from a human immune scFv antibody phage display library. Toxins. 2016;8:266. doi: 10.3390/toxins8090266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins8090266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wu C, Yu J, et al.  Structural basis of tetanus toxin neutralization by native human monoclonal antibodies. Cell Rep. 2021;35:109070. doi: 10.1016/j.celrep.2021.109070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2021.109070</ArticleId>
            <ArticleId IdType="pubmed">33951441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ward NL, Kavlick KD, Diaconu D, Dawes SM, Michaels KA, Gilbert E. Botulinum neurotoxin A decreases infiltrating cutaneous lymphocytes and improves acanthosis in the KC-Tie2 mouse model. J Invest Dermatol. 2012;132:1927–1930. doi: 10.1038/jid.2012.60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jid.2012.60</ArticleId>
            <ArticleId IdType="pmc">PMC3375348</ArticleId>
            <ArticleId IdType="pubmed">22418873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weise D, Weise CM, Naumann M. Central effects of botulinum neurotoxin-evidence from human studies. Toxins. 2019;11:21. doi: 10.3390/toxins11010021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins11010021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiegand H, Erdmann G, Wellhoner HH. 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol. 1976;292:161–165. doi: 10.1007/BF00498587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00498587</ArticleId>
            <ArticleId IdType="pubmed">59905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witmanowski H, Błochowiak K. The whole truth about botulinum toxin—a review. Postepy Dermatol Allergol. 2020;37:853–861. doi: 10.5114/ada.2019.82795.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5114/ada.2019.82795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wright GP. The neurotoxins of Clostridium botulinum and Clostridium tetani. Pharmacol Rev. 1955;7:413–465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13289310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaguchi T, Sano K, Takakura K, et al.  Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group Stroke. 1998;29:12–17.</Citation>
        </Reference>
        <Reference>
          <Citation>Yao G, Zhang S, Mahrhold S, et al.  N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A. Nat Struct Mol Biol. 2016;23:656–662. doi: 10.1038/nsmb.3245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nsmb.3245</ArticleId>
            <ArticleId IdType="pmc">PMC5033645</ArticleId>
            <ArticleId IdType="pubmed">27294781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeh FL, Dong M, Yao J, et al.  SV2 mediates entry of tetanus neurotoxin into central neurons. PLoS Pathog. 2010;6:e1001207. doi: 10.1371/journal.ppat.1001207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1001207</ArticleId>
            <ArticleId IdType="pmc">PMC2991259</ArticleId>
            <ArticleId IdType="pubmed">21124874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yiannakopoulou E. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology. 2015;95:65–69. doi: 10.1159/000370245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000370245</ArticleId>
            <ArticleId IdType="pubmed">25613637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanchi M, Favot F, Bizzarini M, et al.  Botulinum toxin type-A for the treatment of inverse psoriasis. J Eur Acad Dermatol Venereol. 2008;22:431–436. doi: 10.1111/j.1468-3083.2007.02457.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-3083.2007.02457.x</ArticleId>
            <ArticleId IdType="pubmed">18363911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanetti G, Azarnia Tehran D, Pirazzini M, et al.  Inhibition of botulinum neurotoxins interchain disulfide bond reduction prevents the peripheral neuroparalysis of botulism. Biochem Pharmacol. 2015;98:522–530. doi: 10.1016/j.bcp.2015.09.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2015.09.023</ArticleId>
            <ArticleId IdType="pubmed">26449594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanetti G, Mattarei A, Lista F, Rossetto O, Montecucco C, Pirazzini M. Novel small molecule inhibitors that prevent the neuroparalysis of tetanus neurotoxin. Pharmaceuticals. 2021;14:1134. doi: 10.3390/ph14111134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ph14111134</ArticleId>
            <ArticleId IdType="pmc">PMC8618345</ArticleId>
            <ArticleId IdType="pubmed">34832916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Varnum SM. The receptor binding domain of botulinum neurotoxin serotype C binds phosphoinositides. Biochimie. 2012;94:920–923. doi: 10.1016/j.biochi.2011.11.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biochi.2011.11.004</ArticleId>
            <ArticleId IdType="pmc">PMC3277684</ArticleId>
            <ArticleId IdType="pubmed">22120109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S, Masuyer G, Zhang J, et al.  Identification and characterization of a novel botulinum neurotoxin. Nat Commun. 2017;8:14130. doi: 10.1038/ncomms14130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms14130</ArticleId>
            <ArticleId IdType="pmc">PMC5543303</ArticleId>
            <ArticleId IdType="pubmed">28770820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S, Lebreton F, Mansfield MJ, et al.  Identification of a botulinum neurotoxin-like toxin in a commensal strain of Enterococcus faecium. Cell Host Microbe. 2018;23:169–176. doi: 10.1016/j.chom.2017.12.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2017.12.018</ArticleId>
            <ArticleId IdType="pmc">PMC5926203</ArticleId>
            <ArticleId IdType="pubmed">29396040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang G, Yu R, Chi X, et al.  Tetanus vaccine-induced human neutralizing antibodies provide full protection against neurotoxin challenge in mice. Int Immunopharmacol. 2021;91:107297. doi: 10.1016/j.intimp.2020.107297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2020.107297</ArticleId>
            <ArticleId IdType="pubmed">33360088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y, Yu S, Zhao J, et al.  Effectiveness and safety of botulinum toxin type A in the treatment of androgenetic alopecia. Biomed Res Int. 2020;2020:1–7. doi: 10.1155/2020/1501893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2020/1501893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ziade M, Domergue S, Batifol D, et al.  Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomised study. J Plast Reconstr Aesthet Surg. 2013;66:209–214. doi: 10.1016/j.bjps.2012.09.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bjps.2012.09.012</ArticleId>
            <ArticleId IdType="pubmed">23102873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zornetta I, Azarnia Tehran D, Arrigoni G, et al.  The first non Clostridial botulinum-like toxin cleaves VAMP within the juxtamembrane domain. Sci Rep. 2016;6:30257. doi: 10.1038/srep30257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep30257</ArticleId>
            <ArticleId IdType="pmc">PMC4957215</ArticleId>
            <ArticleId IdType="pubmed">27443638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuverink M, Bluma M, Barbieri JT, Krantz B. Tetanus toxin cis-loop contributes to light-chain translocation. mSphere. 2020;5:e00244-20. doi: 10.1128/mSphere.00244-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mSphere.00244-20</ArticleId>
            <ArticleId IdType="pmc">PMC7203457</ArticleId>
            <ArticleId IdType="pubmed">32376703</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
